Breaking News

INKT

MiNK Therapeutics

13
Jun

03/22/23 Evercore ISI: MiNK Therapeutics price target lowered to $3 from $4 at Evercore ISI

08/10/22 H.C. Wainwright: MiNK Therapeutics initiated with a Buy at H.C. Wainwright

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Hot Stocks	MiNK Therapeutics presents clinical data on allogeneic iNKT cells » 08:45 05/22/23 05/22 08:45 05/22/23 08:45 INKT MiNK Therapeutics $1.78 / +0.04 (+2.30%) MiNK Therapeutics… MiNK Therapeutics announced presentation of clinical data from its allo-iNKTs in COVID-19 associated Acute Respiratory Distress Syndrome at the American Thoracic Society International Conference in Washington D.C. Twenty patients with moderate to severe CARDS, including 4 patients on venovenous extracorporeal membrane oxygenation therapy, were treated with a single dose of agenT-797. Clinical results showed pronounced survival benefit and manageable safety profile including: Patients on VV ECMO treated with agenT-797 had 75% 90-day survival compared to 30% survival with in-hospital controls. agenT-797 was dosed to 1 billion cells with a tolerable safety profile, without oxygenation failure or other significant adverse events, including cytokine release syndrome. agenT-797 induced significant anti-inflammatory profile changes and improved lung function within 24 hours after administration in a patient on VV ECMO support. In the overall study, agenT-797 showed reduction in secondary infections, including an over 80% reduction in pneumonia at dose cohort 3 Bacterial pneumonia in one patient on VV ECMO cleared 12 days post-infusion of agenT-797. ShowHide Related Items >><< Company News Street Research Earnings Events INKT MiNK Therapeutics $1.78 / +0.04 (+2.30%) 05/18/23 MiNK Therapeutics presents preclinical data on FAP-CAR-iNKT 04/18/23 MiNK Therapeutics announces clinical data of allogeneic iNKT cells INKT MiNK Therapeutics $1.78 / +0.04 (+2.30%) 03/22/23 Evercore ISI MiNK Therapeutics price target lowered to $3 from $4 at Evercore ISI 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright INKT MiNK Therapeutics $1.78 / +0.04 (+2.30%) 05/11/23 MiNK Therapeutics reports Q1 EPS (17c), consensus (24c) 03/21/23 MiNK Therapeutics reports Q4 EPS (23c), consensus (21c) 06/13/23 MiNK Therapeutics, Inc.
Hot Stocks	MiNK Therapeutics presents preclinical data on FAP-CAR-iNKT » 08:39 05/18/23 05/18 08:39 05/18/23 08:39 INKT MiNK Therapeutics $1.77 / +0.075 (+4.42%) MiNK Therapeutics… MiNK Therapeutics presented preclinical data demonstrating the potential of its novel FAP-CAR-iNKT candidate, MiNK-215, at the American Society of Gene and Cell Therapy, ASGCT, annual meeting. "MiNK-215 is a powerful and innovative cell therapy that addresses resistance in solid tumor cancers," stated Dr. Marc Van Dijk, CSO of MiNK. "Our growing data strengthens our understanding of MiNK-215's effectiveness in combating the suppressive tumor microenvironment and enhancing other immune cells. We believe this novel therapeutic candidate may address challenging solid tumor cancers. We are advancing this program through development and manufacturing, with an IND filing expected next year." MiNK-215, an allogeneic FAP-CAR-IL-15 iNKT cell product, is designed to target fibroblast activation protein expressing cancer-associated fibroblasts and/or tumor cells. Preclinical findings revealed potent anti-tumor activity, including: Robust efficacy in non-small cell lung cancer models, resulting in substantial tumor elimination in the lungs and improved survival compared to T cells alone. Increased killing capacity of partially exhausted T cells, consistent with native iNKT cells' mechanisms. Targeting and elimination of FAP-expressing CAFs, disrupting the tumor-promoting stromal network and reducing immunosuppression in the tumor microenvironment. Enhanced immune cell infiltration and T cell activation, promoting a potent anti-tumor immune response. Augmented persistence and transactivation of effector immune cells through IL-15 secretion. ShowHide Related Items >><< Company News Street Research Earnings Events INKT MiNK Therapeutics $1.77 / +0.075 (+4.42%) 04/18/23 MiNK Therapeutics announces clinical data of allogeneic iNKT cells INKT MiNK Therapeutics $1.77 / +0.075 (+4.42%) 03/22/23 Evercore ISI MiNK Therapeutics price target lowered to $3 from $4 at Evercore ISI 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright INKT MiNK Therapeutics $1.77 / +0.075 (+4.42%) 05/11/23 MiNK Therapeutics reports Q1 EPS (17c), consensus (24c) 03/21/23 MiNK Therapeutics reports Q4 EPS (23c), consensus (21c) 06/13/23 MiNK Therapeutics, Inc.
Earnings	MiNK Therapeutics reports Q1 EPS (17c), consensus (24c) » 08:02 05/11/23 05/11 08:02 05/11/23 08:02 INKT MiNK Therapeutics $1.54 / -0.17 (-9.94%) "This quarter we… "This quarter we have achieved significant progress across our iNKT cell platform. Our lead program, agenT-797, has shown pioneering data in advanced solid cancers at AACR and we have launched expansion studies in anti-PD-1 refractory NSCLC and gastric cancer", said Dr. Jennifer Buell, President and CEO at MiNK. "We are proud to remain the most clinically advanced allo-iNKT company with robust manufacturing capabilities and a novel pipeline of next generation therapies, including our novel FAP-CAR-iNKT." ShowHide Related Items >><< Company News Street Research Earnings Events INKT MiNK Therapeutics $1.54 / -0.17 (-9.94%) 04/18/23 MiNK Therapeutics announces clinical data of allogeneic iNKT cells INKT MiNK Therapeutics $1.54 / -0.17 (-9.94%) 03/22/23 Evercore ISI MiNK Therapeutics price target lowered to $3 from $4 at Evercore ISI 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright 05/11/22 B. Riley MiNK Therapeutics price target lowered to $7 from $10 at B. Riley INKT MiNK Therapeutics $1.54 / -0.17 (-9.94%) 03/21/23 MiNK Therapeutics reports Q4 EPS (23c), consensus (21c) 05/11/23 MiNK Therapeutics - INKT 06/13/23 MiNK Therapeutics, Inc.

Over a month ago
Hot Stocks	MiNK Therapeutics announces clinical data of allogeneic iNKT cells » 13:35 04/18/23 04/18 13:35 04/18/23 13:35 INKT MiNK Therapeutics $2.13 / -0.035 (-1.62%) MiNK Therapeutics… MiNK Therapeutics presented data at the American Association of Cancer Research annual meeting, demonstrating the clinical benefit of allo-iNKTs, agenT-797, alone and in combination with anti-PD-1 in patients with refractory non-small cell lung cancer, testicular, and gastric cancers. In a phase 1/2 trial, patients received a single infusion of agenT-797, alone or in combination with pembro or nivo, without lymphodepletion. Patients were heavily pretreated with a median of 4 prior lines of therapy and were unresponsive to prior anti-PD-1 therapy. The results showed that agenT-797 promoted durable responses, including a partial response and tumor reduction of greater than42% which was ongoing at 9 months in a patient with metastatic gastric cancer who had no response to prior treatment with pembro or nivo plus FOLFOX. Additionally, durable disease stabilization and biomarker responses were observed in NSCLC and testicular cancers refractory to anti-PD-1. AgenT-797 was persistent and detectable in the periphery for greater than ~8 weeks and tolerable up to 1000x106 cells, with no neurotoxicity, dose-limiting toxicities, or severe cytokine release syndrome. Administration of agenT-797 induced a systemic and local anti-tumor response, driving immune cell infiltration into tumors and promoting immune cell activation. MiNK Therapeutics will further evaluate agenT-797 through phase 1/2 expansion trials in combination with standard of care agents with or without botensilimab in relapsed/refractory NSCLC, testicular cancer, and in 2L gastric cancer through a phase 1/2 investigator sponsored trial led by Dr. Yelena Janjigian, Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center. ShowHide Related Items >><< Company News Street Research Earnings INKT MiNK Therapeutics $2.13 / -0.035 (-1.62%) 11/10/22 MiNK Therapeutics presents clinical data at SITC 2022 INKT MiNK Therapeutics $2.13 / -0.035 (-1.62%) 03/22/23 Evercore ISI MiNK Therapeutics price target lowered to $3 from $4 at Evercore ISI 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright 05/11/22 B. Riley MiNK Therapeutics price target lowered to $7 from $10 at B. Riley INKT MiNK Therapeutics $2.13 / -0.035 (-1.62%) 03/21/23 MiNK Therapeutics reports Q4 EPS (23c), consensus (21c) 11/03/22 MiNK Therapeutics reports Q3 EPS (19c), consensus (23c)
Recommendations	MiNK Therapeutics price target lowered to $3 from $4 at Evercore ISI » 10:57 03/22/23 03/22 10:57 03/22/23 10:57 INKT MiNK Therapeutics $2.02 / -0.12 (-5.61%) Evercore ISI lowered the… Evercore ISI lowered the firm's price target on MiNK Therapeutics to $3 from $4 and keeps an Outperform rating on the shares. MiNK Therapeutics will be presenting data for its allogenic iNKT cells as monotherapy and in combination with PD-1 antibody at the upcoming AACR conference. Currently, tumor pseudo progression with PD-1 therapy alone can occur in as many as 4/17 gastric cancer patients with progressive disease on PD-1 therapy, which is a "fairly high bar" for what the firm is looking for in the combo patients. Furthermore, the company will need to find strategic partners to help advance its program. At the moment, management seems optimistic it will be able to check both the data and the partnership boxes, leading Evercore ISI to maintain an Outperform rating on the shares. ShowHide Related Items >><< Company News Street Research Earnings INKT MiNK Therapeutics $2.02 / -0.12 (-5.61%) 11/10/22 MiNK Therapeutics presents clinical data at SITC 2022 INKT MiNK Therapeutics $2.02 / -0.12 (-5.61%) 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright 05/11/22 B. Riley MiNK Therapeutics price target lowered to $7 from $10 at B. Riley INKT MiNK Therapeutics $2.02 / -0.12 (-5.61%) 03/21/23 MiNK Therapeutics reports Q4 EPS (23c), consensus (21c) 11/03/22 MiNK Therapeutics reports Q3 EPS (19c), consensus (23c)
Earnings	MiNK Therapeutics reports Q4 EPS (23c), consensus (21c) » 08:04 03/21/23 03/21 08:04 03/21/23 08:04 INKT MiNK Therapeutics $2.06 / -0.14 (-6.36%) "2022 has been an… "2022 has been an important year for MiNK, with significant progress across our clinical and preclinical programs in iNKT cell therapy, bolstered by the expansion of our in-house manufacturing capabilities," stated Dr. Jennifer Buell, President and Chief Executive Officer of MiNK. "Our advancements have solidified MiNK's position as a leader in the iNKT cell therapy field, with a growing body of clinical data demonstrating the potential of iNKT cells alone and in combination with standard of care agents, as well as novel insights into their unique mechanisms of action. Additionally, we've made strides in our CAR-iNKT program. As we move into 2023, we are eager to build on this momentum and rapidly expand our solid tumor program, leveraging our strong foundation to accelerate the development of potentially life-saving therapies for patients." ShowHide Related Items >><< Company News Street Research Earnings Events INKT MiNK Therapeutics $2.06 / -0.14 (-6.36%) 11/10/22 MiNK Therapeutics presents clinical data at SITC 2022 INKT MiNK Therapeutics $2.06 / -0.14 (-6.36%) 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright 05/11/22 B. Riley MiNK Therapeutics price target lowered to $7 from $10 at B. Riley INKT MiNK Therapeutics $2.06 / -0.14 (-6.36%) 11/03/22 MiNK Therapeutics reports Q3 EPS (19c), consensus (23c) 03/21/23 MiNK Therapeutics - INKT

Over a quarter ago
Conference/Events	Society for Immunotherapy of Cancer to hold a meeting » 04:55 11/12/22 11/12 04:55 11/12/22 04:55 ABMD Abiomed $373.89 / +1.235 (+0.33%) , ADPT Adaptive Biotechnologies $9.32 / +0.23 (+2.53%) , ALKS Alkermes $23.57 / -0.685 (-2.82%) , AMGN Amgen $284.92 / -6.02 (-2.07%) , ASND Ascendis Pharma $131.96 / +2.47 (+1.91%) , BMY Bristol-Myers $75.92 / -3.44 (-4.33%) , CGEN Compugen / + , CLRB Cellectar Biosciences $1.90 / +0.01 (+0.53%) , CRL Charles River $246.43 / +8.49 (+3.57%) , INKT MiNK Therapeutics $2.99 / +0.81 (+37.16%) , INCY Incyte $77.54 / -0.21 (-0.27%) , PHIO Phio Pharmaceuticals / + , INBX Inhibrx $32.72 / +0.57 (+1.77%) , XNCR Xencor $29.42 / -1.07 (-3.51%) , VCYT Veracyte $29.95 / +1.915 (+6.83%) , TXG 10x Genomics $41.29 / +3.51 (+9.29%) , TPST Tempest Therapeutics $1.73 / +0.2 (+13.07%) , TMO Thermo Fisher $539.07 / +18.83 (+3.62%) , TIL Instil Bio $2.26 / -0.16 (-6.63%) , SGEN Seagen $132.82 / +1.77 (+1.35%) , REGN Regeneron $734.49 / -7.28 (-0.98%) , REPL Replimune Group $21.02 / +0.89 (+4.42%) , RHHBY Roche $43.25 / +0.72 (+1.69%) , DNA Ginkgo Bioworks $2.86 / +0.225 (+8.56%) , CUE Cue Biopharma $3.11 / +0.03 (+0.97%) , IOVA Iovance Biotherapeutics $8.87 / +0.205 (+2.37%) , IPSC Century Therapeutics $10.95 / -0.64 (-5.52%) , LH Labcorp $249.20 / +6.07 (+2.50%) , MRK Merck $97.90 / -3.91 (-3.84%) , MXCT MaxCyte $7.13 / +0.085 (+1.21%) , EXEL Exelixis $16.78 / -0.105 (-0.62%) , FATE Fate Therapeutics $22.95 / +1.99 (+9.49%) , GMAB Genmab $41.84 / -1.67 (-3.84%) 37th Annual Meeting SITC… 37th Annual Meeting SITC 2022 to be held in Boston on November 8-12. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options XNCR VCYT TXG TPST TMO TIL SGEN RHHBY REPL REGN PHIO MXCT MRK LH IPSC IOVA INKT INCY INBX GMAB FATE EXEL DNA CUE CRL CLRB CGEN BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $29.42 / -1.07 (-3.51%) 10/20/22 SpikImm enters non-exclusive in-license agreement with Xencor 08/02/22 Xencor enters multi-year option, license agreement with Caris Life Sciences 05/26/22 Xencor reports initial dose-escalation Phase 1 data of XmAb 104 VCYT Veracyte $29.95 / +1.915 (+6.83%) 10/17/22 Exagen appoints John Aballi as CEO 09/22/22 Veracyte announces VANDAAM trial data published in journal 09/11/22 Veracyte announces new data from Phase 3 of STAMPEDE platform protocol 09/07/22 Veracyte's Envisia Genomic Classifier may predict lung disease progression TXG 10x Genomics $41.29 / +3.51 (+9.29%) 11/03/22 10x Genomics trading resumes 11/03/22 10x Genomics trading halted, volatility trading pause 08/02/22 Singular Genomics appoints Ropp as Chief Commercial Officer 07/14/22 10x Genomics drops 17% to $36.00 after Q2 revenue guidance misses estimates TPST Tempest Therapeutics $1.73 / +0.2 (+13.07%) 11/10/22 Tempest Therapeutics presents data on TPST-1120 10/06/22 Tempest Therapeutics to present on TREX1 at Emerging Technologies summit 08/15/22 Tempest Therapeutics announces near-term milestones 08/15/22 Tempest Therapeutics sees cash runway into 1Q24 TMO Thermo Fisher $539.07 / +18.83 (+3.62%) 11/10/22 Thermo Fisher authorizes $4B in share repurchases 10/31/22 Cytek Biosciences appoints Chris Williams as COO 10/31/22 Thermo Fisher announces $1B share repurchase program for Q4 10/31/22 Thermo Fisher to acquire The Binding Site Group for $2.6B in accretive deal TIL Instil Bio $2.26 / -0.16 (-6.63%) 11/08/22 Instil Bio announces poster presentations of CoSTAR platform 10/31/22 Instil Bio announces voluntary pause of enrollment in ongoing trials 10/18/22 Instil Bio announces first patient dosed with ITIL-306 09/06/22 Instil Bio appoints Tim Moore as COO SGEN Seagen $132.82 / +1.77 (+1.35%) 11/10/22 Seagen announces FDA approval for Adcetris in new indication 11/10/22 Seagen appoints David Epstein as CEO 09/27/22 Seagen, Zai Lab enter regional collaboration, license agreement for TIVDAK 09/27/22 Seagen to be paid $30M up-front in Zai Lab deal for Tivdak development in China RHHBY Roche $43.25 / +0.72 (+1.69%) 11/10/22 Oncolytics' pelareorep shows 69% response rate in pancreatic cancer study 11/09/22 Roche announces publication of STRONG-HF study 11/07/22 Oncolytics reports interim results from Phase 1/2 GOBLET study 10/27/22 Genentech announces both BALATON, COMINO trials met primary endpoint REPL Replimune Group $21.02 / +0.89 (+4.42%) 11/03/22 Replimune Group: Financing extends cash runway into 2025 10/07/22 Replimune Group secures $200M debt financing from Hercules Capital 08/04/22 Replimune Group expects cash to fund operations into 2H of 2024 06/28/22 Revolution Medicines announces election of Patel to board of directors REGN Regeneron $734.49 / -7.28 (-0.98%) 11/11/22 Regeneron and Sanofi's Dupixent recommended for EU approval in prurigo nodularis 11/11/22 Regeneron, Sanofi announce CHMP recommendation for Dupixent approval 11/09/22 USPTO board says Mylan has shown claims of Regeneron patent 'unpatentable' 11/08/22 Regeneron: FDA approves Libtayo in combination with platinum-based chemotherapy PHIO Phio Pharmaceuticals / + 09/22/22 Phio Pharmaceuticals' PH-894 shows increased T-cell persistence 06/06/22 Phio Pharmaceuticals presents outline for first study of PH-762 for melanoma 05/16/22 Phio Pharmaceuticals' PH-894 shows enhanced HER2-CAR-T cell activity MXCT MaxCyte $7.13 / +0.085 (+1.21%) 09/28/22 MaxCyte signs strategic platform license with Vertex Pharmaceuticals 09/21/22 MaxCyte debuts new headquarters in Maryland's I-270 Biotech Corridor 07/12/22 MaxCyte signs strategic platform with LG Chem MRK Merck $97.90 / -3.91 (-3.84%) 11/11/22 Intensity Therapeutics' INT230-6 increases survival in solid tumor cancers 11/10/22 Immutep announces clinical results from Phase II trial of eftilagimod alpha 11/10/22 Nektar's NKTR-288 shows enhanced anti-tumor activity in LH Labcorp $249.20 / +6.07 (+2.50%) 10/13/22 Labcorp appoints Google Cloud exec Kliphouse to board of directors 08/23/22 Labcorp closes acquisition of RWJBarnabas Health outreach laboratory business 08/15/22 JANA Partners exits Zendesk, boosts stake in New Relic 08/09/22 Becton Dickinson, Labcorp announce CDx collaboration agreement IPSC Century Therapeutics $10.95 / -0.64 (-5.52%) 11/11/22 Century Therapeutics presents preclinical data at SITC meeting 11/10/22 Century Therapeutics sees cash runway into 2025 10/03/22 Century Therapeutics appoints Daphne Quimi, Timothy Walbert to board 08/25/22 Century Therapeutics receives Study May Proceed notification for CNTY-101 IOVA Iovance Biotherapeutics $8.87 / +0.205 (+2.37%) 11/10/22 Iovance Biotherapeutics announces updated clinical data for lifileucel 11/07/22 Iovance Biotherapeutics announces updated clinical data for Lifileucel 10/10/22 Iovance Biotherapeutics doses first patient with PD-1 inactivated TIL therapy 08/25/22 Iovance Biotherapeutics initiates BLA submission for lifileucel INKT MiNK Therapeutics $2.99 / +0.81 (+37.16%) 11/10/22 MiNK Therapeutics presents clinical data at SITC 2022 INCY Incyte $77.54 / -0.21 (-0.27%) 11/07/22 Incyte, Mirati Therapeutics enter INCB99280 clinical trial and supply pact 10/19/22 Incyte's ruxolitinib cream shows repigmentation efficacy in Phase 3 trial 10/12/22 BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate 10/12/22 BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate INBX Inhibrx $32.72 / +0.57 (+1.77%) 10/04/22 Inhibrx announce potential to pursue accelerated approval in U.S. for INBRX-101 08/15/22 Inhibrx: EMA grants orphan drug designation to INBRX-109 06/30/22 Inhibrx completes Phase 1 dose escalation for INBRX-105, draws $60M loan 05/16/22 Inhibrx's INBRX-101 shows favorable safety profile in Phase 1 AATD trial GMAB Genmab $41.84 / -1.67 (-3.84%) 10/28/22 Genmab submits subcutaneous epcoritamab BLA to FDA 10/28/22 AbbVie: EMA validates MAA for epcoritamab 10/18/22 Genmab reports Q3 worldwide net sales of DARZALEX $2.05B FATE Fate Therapeutics $22.95 / +1.99 (+9.49%) 11/07/22 Fate announces exercise by ONO of option to FT825/ONO-8250 08/11/22 Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today 08/09/22 Fate Therapeutics announces preclinical study results on iPSCs 06/30/22 Fate Therapeutics appoints Brian Powl Chief Commercial Officer EXEL Exelixis $16.78 / -0.105 (-0.62%) 11/01/22 Exelixis, Cybrexa establish exclusive collaboration 11/01/22 Exelixis, Sairopa establish development collaboration, option agreement 10/26/22 Exelixis announces initial results from dose-escalation stage of JEWEL-101 10/04/22 Exelixis expands pact with Bristol-Myers for STELLAR-002 trial with combos DNA Ginkgo Bioworks $2.86 / +0.225 (+8.56%) 11/11/22 Ginkgo Bioworks and Lygos partner to optimize production of biobased chemicals 10/25/22 Ginkgo Bioworks selected by Saudi Arabia for biotechnology initiatives 10/20/22 Ginkgo Bioworks collaborates with Bolt Threads for optimization of Mylo material 10/19/22 Ginkgo Bioworks completes acquisition of Zymergen CUE Cue Biopharma $3.11 / +0.03 (+0.97%) 11/10/22 Cue Biopharma reports new data from ongoing Phase 1 trial of CUE-101 combo 10/04/22 Cue Biopharma's CUE-101 granted Fast Track designation for treatment of NSCC 09/07/22 Cue Biopharma to present at two September scientific conferences 08/22/22 Cue Biopharma doses 1st patient in CUE-102 study for Wilms' Tumor cancer CRL Charles River $246.43 / +8.49 (+3.57%) 11/07/22 Charles River expands CDMO facility in Memphis 11/02/22 Charles River rises 10.6% 11/02/22 Charles River: 'Well-positioned' to finish 2022 on strong note 11/02/22 Charles River to divest Avian Vaccine unit for $170M in cash plus payments CLRB Cellectar Biosciences $1.90 / +0.01 (+0.53%) 10/21/22 Cellectar announces concurrent registered direct, private placement offerings 09/22/22 Cellectar awarded $2M grant to expand Phase 1 study iopofosine I 131 09/13/22 Cellectar announces publication of data from its Phase 2 CLOVER-1 study 08/05/22 Cellectar Biosciences expects cash to fund operations into 3Q23 CGEN Compugen / + 11/07/22 Compugen's COM701 shows preliminary anti-tumor activity in MSS-CRC patients 11/03/22 Compugen announces receipt of Nasdaq delisting notice 09/12/22 Compugen names Alberto Sessa as CFO 08/24/22 Compugen awarded new patent from Japan Patent Office BMY Bristol-Myers $75.92 / -3.44 (-4.33%) 11/07/22 Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports 11/03/22 Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital 10/31/22 Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints 10/27/22 Obsidian Therapeutics announces extension of agreement with Bristol-Myers ASND Ascendis Pharma $131.96 / +2.47 (+1.91%) 11/11/22 Ascendis Pharma presents dose-escalation data from transcendIT-101 10/31/22 Ascendis announces FDA accepted priority review of its NDA for TransCon PTH 10/03/22 Crinetics appoints Dana Pizzuti as CDO 10/03/22 Ascendis announces recommended Phase 2 dose for transcendIT-101 AMGN Amgen $284.92 / -6.02 (-2.07%) 11/09/22 Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead 11/09/22 Arrowhead sells royalty interest in olpasiran to Royalty Pharma for $250M+ 11/07/22 Amgen presents new Repatha data at AHA 2022 11/06/22 Amgen presents end-of-treatment data from Phase 2 OCEAN(a)-DOSE study ALKS Alkermes $23.57 / -0.685 (-2.82%) 11/02/22 Alkermes announces plans to separate oncology business 10/16/22 Acorda announces $16.5M award, royalty/supply relief in AMPYRA arbitration case 10/07/22 Sarissa Capital reports 8.55% stake in Alkermes, may seek to boost stake 07/06/22 Sarissa to vote for Alkermes director slate, still seeks board seat ADPT Adaptive Biotechnologies $9.32 / +0.23 (+2.53%) 10/11/22 Adaptive Biotechnologies partners with Epic to increase access to MRD monitoring 08/25/22 Cathie Wood's ARK Investment bought 155.4K shares of Adaptive Biotech today 07/28/22 Adaptive Biotechnologies receives expanded Medicare coverage of clonoSEQ 06/15/22 Adaptive Biotechnologies launches T-Detect Lyme ABMD Abiomed $373.89 / +1.235 (+0.33%) 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 11/01/22 J&J: Abiomed acquisition has enterprise value of $16.6B 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 10/31/22 Abiomed announces Impella RP Flex with SmartAssist receives FDA PMA ABMD ADPT ALKS AMGN ASND BMY CGEN CLRB CRL INKT INCY PHIO INBX XNCR VCYT TXG TPST TMO TIL SGEN REGN REPL RHHBY DNA CUE IOVA IPSC LH MRK MXCT EXEL FATE GMAB ABMD Abiomed $373.89 / +1.235 (+0.33%) 11/02/22 Morgan Stanley Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/22 Deutsche Bank Abiomed downgraded to Hold from Buy at Deutsche Bank 11/01/22 William Blair Abiomed downgraded to Market Perform from Outperform at William Blair 11/01/22 Piper Sandler Abiomed downgraded to Neutral from Overweight at Piper Sandler ADPT Adaptive Biotechnologies $9.32 / +0.23 (+2.53%) 10/26/22 Piper Sandler Natera named top pick in minimal residual disease at Piper Sandler 10/26/22 Piper Sandler Adaptive price target lowered to $7.50 from $12 at Piper Sandler 08/24/22 Credit Suisse Adaptive Biotechnologies initiated with an Underperform at Credit Suisse 08/17/22 Piper Sandler Adaptive Biotechnologies price target raised to $12 from $7.50 at Piper Sandler ALKS Alkermes $23.57 / -0.685 (-2.82%) 11/03/22 Piper Sandler Alkermes upgraded to Overweight from Neutral at Piper Sandler 10/20/22 Mizuho Alkermes Q3 miss may be largely priced in, says Mizuho 10/19/22 Piper Sandler Alkermes shares have more downside risk, says Piper Sandler 10/14/22 BofA Alkermes upgraded to Neutral at BofA on improved risk/reward AMGN Amgen $284.92 / -6.02 (-2.07%) 11/08/22 Oppenheimer Amgen price target raised to $300 from $290 at Oppenheimer 11/08/22 Truist Amgen price target raised to $280 from $266 at Truist 11/04/22 Piper Sandler Amgen price target raised to $278 from $265 at Piper Sandler 10/31/22 Barclays Amgen downgraded to Underweight from Equal Weight at Barclays ASND Ascendis Pharma $131.96 / +2.47 (+1.91%) 11/03/22 Oppenheimer Ascendis Pharma price target raised to $150 from $144 at Oppenheimer 11/03/22 Wedbush Ascendis Pharma price target raised to $151 from $144 at Wedbush 11/03/22 Credit Suisse Ascendis Pharma price target raised to $130 from $123 at Credit Suisse 11/03/22 Citi Ascendis Pharma price target raised to $163 from $157 at Citi BMY Bristol-Myers $75.92 / -3.44 (-4.33%) 11/02/22 Evercore ISI Evercore starts Legend Biotech with an Outperform on Carvykti potential 10/31/22 Guggenheim 2seventy Bio initiated with a Buy at Guggenheim 10/12/22 Barclays Bristol-Myers price target lowered to $66 from $69 at Barclays 10/10/22 Guggenheim Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials CGEN Compugen / + 08/23/22 Truist Compugen price target lowered to $4 from $14 at Truist 08/08/22 JMP Securities Compugen price target lowered to $4 from $8 at JMP Securities 08/05/22 Jefferies Jefferies downgrades Compugen to Hold with cash likely becoming 'growing issue' 08/05/22 Jefferies Compugen downgraded to Hold from Buy at Jefferies CLRB Cellectar Biosciences $1.90 / +0.01 (+0.53%) 11/08/22 Maxim Cellectar Biosciences price target lowered to $7 from $12.50 at Maxim 11/04/22 Oppenheimer Cellectar Biosciences price target lowered to $12 from $47 at Oppenheimer 07/18/22 Oppenheimer Cellectar Biosciences assumed with an Outperform at Oppenheimer 04/07/22 Ladenburg Cellectar Biosciences transferred with a Buy at Ladenburg CRL Charles River $246.43 / +8.49 (+3.57%) 11/03/22 Credit Suisse Charles River price target lowered to $280 from $285 at Credit Suisse 09/30/22 Jefferies Charles River upgraded to Buy at Jefferies on nonhuman primate tailwinds 09/29/22 Jefferies Charles River upgraded to Buy from Hold at Jefferies 08/24/22 Credit Suisse Charles River initiated with an Outperform at Credit Suisse INKT MiNK Therapeutics $2.99 / +0.81 (+37.16%) 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright 05/11/22 B. Riley MiNK Therapeutics price target lowered to $7 from $10 at B. Riley 01/24/22 B. Riley MiNK Therapeutics price target lowered to $10 from $24 at B. Riley INCY Incyte $77.54 / -0.21 (-0.27%) 10/24/22 JPMorgan Incyte price target lowered to $80 from $86 at JPMorgan 08/03/22 Evercore ISI Incyte downgraded to In Line from Outperform at Evercore ISI 08/03/22 Guggenheim Incyte downgraded to Neutral at Guggenheim after Opzelura Q2 miss 08/03/22 Oppenheimer Incyte price target lowered to $98 from $109 at Oppenheimer PHIO Phio Pharmaceuticals / + INBX Inhibrx $32.72 / +0.57 (+1.77%) 10/05/22 Evercore ISI Inhibrx price target raised to $60 from $54 at Evercore ISI 08/09/22 Credit Suisse Inhibrx price target lowered to $48 from $53 at Credit Suisse 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko XNCR Xencor $29.42 / -1.07 (-3.51%) 11/09/22 Canaccord Xencor price target lowered to $48 from $50 at Canaccord 11/08/22 Raymond James Xencor added to Analyst Current Favorites list at Raymond James 10/13/22 Raymond James Xencor upgraded to Strong Buy from Outperform at Raymond James 10/13/22 Raymond James Xencor upgraded to Strong Buy from Outperform at Raymond James VCYT Veracyte $29.95 / +1.915 (+6.83%) 05/04/22 Needham Veracyte price target lowered to $26 from $31 at Needham 03/15/22 Needham Needham drops Veracyte target, says shares undervalued 03/01/22 Lake Street Veracyte price target lowered to $50 from $95 at Lake Street 03/01/22 Needham Veracyte price target lowered to $35 from $55 at Needham TXG 10x Genomics $41.29 / +3.51 (+9.29%) 11/03/22 JPMorgan 10x Genomics price target lowered to $55 from $65 at JPMorgan 08/18/22 Goldman Sachs 10x Genomics downgraded to Sell from Neutral at Goldman Sachs 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler 08/10/22 Morgan Stanley 10x Genomics price target lowered to $70 from $100 at Morgan Stanley TPST Tempest Therapeutics $1.73 / +0.2 (+13.07%) 09/15/22 Ladenburg Tempest Therapeutics initiated with a Buy at Ladenburg 05/13/22 Piper Sandler Tempest Therapeutics price target lowered to $10 from $20 at Piper Sandler 05/13/22 H.C. Wainwright Tempest Therapeutics price target lowered to $35 from $51 at H.C. Wainwright 04/27/22 Piper Sandler Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20 TMO Thermo Fisher $539.07 / +18.83 (+3.62%) 11/01/22 Baird Thermo Fisher price target lowered to $665 from $695 at Baird 10/27/22 Morgan Stanley Thermo Fisher price target lowered to $613 from $678 at Morgan Stanley 10/27/22 Baird Thermo Fisher price target lowered to $696 from $711 at Baird 10/27/22 Citi Thermo Fisher price target lowered to $650 from $715 at Citi TIL Instil Bio $2.26 / -0.16 (-6.63%) 11/01/22 TD Cowen Cowen downgrades Instil Bio on manufacturing failures 11/01/22 Truist Instil Bio downgraded to Hold from Buy at Truist 11/01/22 Baird Instil Bio price target lowered to $24 from $31 at Baird 11/01/22 TD Cowen Instil Bio downgraded to Market Perform from Outperform at Cowen SGEN Seagen $132.82 / +1.77 (+1.35%) 10/28/22 Oppenheimer Seagen price target lowered to $188 from $208 at Oppenheimer 10/28/22 H.C. Wainwright Seagen price target lowered to $180 from $200 at H.C. Wainwright 10/24/22 JPMorgan Seagen price target lowered to $155 from $194 at JPMorgan 10/11/22 BMO Capital Seagen upgraded to Outperform from Market Perform at BMO Capital REGN Regeneron $734.49 / -7.28 (-0.98%) 11/09/22 RBC Capital Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital 11/09/22 Truist Regeneron price target raised to $856 from $790 at Truist 11/03/22 Piper Sandler Regeneron price target lowered to $765 from $775 at Piper Sandler 10/31/22 EF Hutton Regeneron initiated with a Buy at EF Hutton REPL Replimune Group $21.02 / +0.89 (+4.42%) 10/14/22 BMO Capital Replimune Group price target raised to $40 from $30 at BMO Capital 08/16/22 Piper Sandler Replimune Group price target lowered to $43 from $44 at Piper Sandler 05/24/22 Wedbush Replimune Group price target lowered to $52 from $59 at Wedbush 05/19/22 Piper Sandler Replimune Group price target lowered to $44 from $52 at Piper Sandler RHHBY Roche $43.25 / +0.72 (+1.69%) 11/11/22 BTIG Poseida Therapeutics price target lowered to $14 from $20 at BTIG 10/25/22 Capital One Arvinas initiated with an Overweight at Capital One 10/17/22 Morgan Stanley Roche's AD drug expected to fall short in trial, says Morgan Stanley 10/12/22 Stifel Biogen upgraded to Buy from Hold at Stifel DNA Ginkgo Bioworks $2.86 / +0.225 (+8.56%) 10/04/22 Morgan Stanley Ginkgo Bioworks initiated with an Equal Weight at Morgan Stanley 08/16/22 BTIG Ginkgo Bioworks price target raised to $6 from $5 at BTIG 08/16/22 Raymond James Ginkgo Bioworks price target raised to $14.50 from $11.50 at Raymond James 07/26/22 William Blair Zymergen buyout deal 'best case scenario,' says William Blair CUE Cue Biopharma $3.11 / +0.03 (+0.97%) 11/10/22 Oppenheimer Cue Biopharma's SITC data a 'big improvement,' says Oppenheimer 08/24/22 Oppenheimer Cue Biopharma price target lowered to $10 from $26 at Oppenheimer 03/23/22 JMP Securities Cue Biopharma price target lowered to $15 from $30 at JMP Securities 03/21/22 Oppenheimer Cue Biopharma price target lowered to $26 from $32 at Oppenheimer IOVA Iovance Biotherapeutics $8.87 / +0.205 (+2.37%) 10/31/22 Guggenheim Iovance Biotherapeutics initiated with a Neutral at Guggenheim 08/18/22 Wells Fargo Iovance Biotherapeutics assumed with an Equal Weight at Wells Fargo 08/08/22 Stifel Global Blood Therapeutics downgraded to Hold from Buy at Stifel IPSC Century Therapeutics $10.95 / -0.64 (-5.52%) 11/11/22 Piper Sandler Century Therapeutics price target raised to $24 at Piper after R&D day 10/31/22 Guggenheim Century Therapeutics initiated with a Buy at Guggenheim 10/10/22 Canaccord Century Therapeutics initiated with a Buy at Canaccord 06/10/22 Roth MKM Century Therapeutics initiated with a Buy at Roth Capital LH Labcorp $249.20 / +6.07 (+2.50%) 11/03/22 Mizuho Labcorp price target lowered to $250 from $296 at Mizuho 10/28/22 Citi Labcorp price target lowered to $275 from $300 at Citi 10/28/22 Baird Labcorp price target lowered to $270 from $297 at Baird 09/19/22 Argus Labcorp downgraded to Hold from Buy at Argus MRK Merck $97.90 / -3.91 (-3.84%) 11/01/22 Oppenheimer Merck pact shows Veeva life science vendor of choice, says Oppenheimer 11/01/22 Guggenheim Merck price target raised to $111 from $104 at Guggenheim 10/28/22 Morgan Stanley Merck price target raised to $100 from $91 at Morgan Stanley 10/28/22 Cantor Fitzgerald Merck price target raised to $120 from $107 at Cantor Fitzgerald MXCT MaxCyte $7.13 / +0.085 (+1.21%) 08/14/22 BTIG MaxCyte price target raised to $11 from $10 at BTIG EXEL Exelixis $16.78 / -0.105 (-0.62%) 11/02/22 TD Cowen Exelixis price target lowered to $21 from $26 at Cowen 10/31/22 EF Hutton Exelixis initiated with a Buy at EF Hutton 10/18/22 JMP Securities Exelixis initiated with an Outperform at JMP Securities 10/12/22 Guggenheim Initial data for Exelixis's XB002 show encouraging safety, says Guggenheim FATE Fate Therapeutics $22.95 / +1.99 (+9.49%) 11/04/22 Cantor Fitzgerald Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald 10/10/22 Canaccord Fate Therapeutics initiated with a Buy at Canaccord 08/18/22 Wells Fargo Fate Therapeutics assumed with an Overweight at Wells Fargo 08/04/22 Oppenheimer Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer GMAB Genmab $41.84 / -1.67 (-3.84%) 11/11/22 Deutsche Bank Genmab downgraded to Hold at Deutsche Bank ahead of ESMO and ASH data 11/11/22 Deutsche Bank Genmab downgraded to Hold from Buy at Deutsche Bank 10/17/22 DNB Markets Genmab downgraded to Hold from Buy at DNB Markets 09/15/22 Credit Suisse Genmab price target raised to DKK 2,800 from DKK 2,600 at Credit Suisse XNCR VCYT TXG TPST TMO TIL SGEN RHHBY REPL REGN MXCT MRK LH IPSC IOVA INKT INCY INBX GMAB FATE EXEL DNA CRL CLRB BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $29.42 / -1.07 (-3.51%) 11/07/22 Xencor reports Q3 EPS (55c), consensus (68c) 08/03/22 Xencor reports Q2 EPS (57c), consensus (44c) VCYT Veracyte $29.95 / +1.915 (+6.83%) 11/02/22 Veracyte raises FY2 revenue view to $288M-$293M from $272M-$280M 11/02/22 Veracyte reports Q3 EPS (12c), consensus (25c) 08/02/22 Veracyte raises FY22 revenue view to $272M-$280M, consensus $272.42M 08/02/22 Veracyte reports Q2 EPS (13c), consensus (22c) TXG 10x Genomics $41.29 / +3.51 (+9.29%) 11/02/22 10x Genomics sees 2022 revenue $500M-$522M, consensus $509.87M 11/02/22 10x Genomics reports Q3 EPS (37c), consensus (46c) 08/08/22 10x Genomics updated FY22 revenue view to $500M-$520M, consensus $571.06M 08/08/22 10x Genomics reports Q2 EPS (57c), consensus (39c) TPST Tempest Therapeutics $1.73 / +0.2 (+13.07%) 11/08/22 Tempest Therapeutics reports Q3 EPS (66c), consensus (80c) 08/15/22 Tempest Therapeutics reports Q2 EPs (79c) vs. ($7.63) last year. 05/13/22 Tempest Therapeutics reports Q1 EPS ($1.18), consensus ($1.12) TMO Thermo Fisher $539.07 / +18.83 (+3.62%) 10/26/22 Thermo Fisher raises FY22 EPS view to $23.01 from $22.93, consensus $22.95 10/26/22 Thermo Fisher reports Q3 adjusted EPS $5.08, consensus $4.82 TIL Instil Bio $2.26 / -0.16 (-6.63%) 08/12/22 Instil Bio reports Q2 adjusted EPS (40c), consensus (41c) 05/16/22 Instil Bio reports Q1 EPS (42c), consensus (38c) SGEN Seagen $132.82 / +1.77 (+1.35%) 10/27/22 Seagen raises FY22 revenue $1.82B-$1.865B from $1.71B-$1.795B 10/27/22 Seagen reports Q3 EPS ($1.03), consensus (95c) 07/28/22 Seagen raises FY22 revenue view to $1.71B-$1.795B from $1.665B-$1.745B 07/28/22 Seagen reports Q2 EPS (73c), consensus (86c) RHHBY Roche $43.25 / +0.72 (+1.69%) 10/18/22 Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year 07/21/22 Roche reports 1H core EPS CHF 11.76 vs. CHF 10.56 last year REPL Replimune Group $21.02 / +0.89 (+4.42%) 11/03/22 Replimune Group reports Q2 EPS (79c), consensus (78c) 08/04/22 Replimune Group reports Q1 EPS (78c) vs (53c) last year 05/19/22 Replimune Group reports 2022 EPS ($2.26), consensus ($2.26) REGN Regeneron $734.49 / -7.28 (-0.98%) 11/03/22 Regeneron reports Q3 EPS $11.14, consensus $9.48 11/02/22 Notable companies reporting before tomorrow's open 08/03/22 Regeneron reports Q2 EPS $9.77, consensus $9.54 MXCT MaxCyte $7.13 / +0.085 (+1.21%) 11/09/22 MaxCyte reports Q3 EPS (6c) consensus (9c) 08/10/22 MaxCyte sees FY22 core business revenue growth of 30% year-over-year 08/10/22 MaxCyte reports Q2 EPS (8c), consensus (8c) MRK Merck $97.90 / -3.91 (-3.84%) 10/27/22 Merck raises FY22 adjusted EPS view to $7.32-$7.37 from $7.25-$7.35 10/27/22 Merck reports Q3 adjusted EPS $1.85, consensus $1.71 10/26/22 Notable companies reporting before tomorrow's open LH Labcorp $249.20 / +6.07 (+2.50%) 10/27/22 Labcorp sees FY22 EPS $19.25- $20.25 , consensus $20.19 10/27/22 Labcorp reports Q3 EPS $4.68, consensus $4.67 07/28/22 LabCorp raises FY22 adjusted EPS view to $19.00-$21.25 from $18.25-$21.00 07/28/22 LabCorp reports Q2 adjusted EPS $4.96, consensus $4.70 IPSC Century Therapeutics $10.95 / -0.64 (-5.52%) 11/10/22 Century Therapeutics reports Q3 EPS (53c), consensus (59c) 08/11/22 Century Therapeutics reports Q2 EPS (54c), consensus (52c) 05/16/22 Century Therapeutics reports Q1 EPS (66c), consensus (45c) IOVA Iovance Biotherapeutics $8.87 / +0.205 (+2.37%) 11/03/22 Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c) 08/04/22 Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c) INKT MiNK Therapeutics $2.99 / +0.81 (+37.16%) 11/03/22 MiNK Therapeutics reports Q3 EPS (19c), consensus (23c) 08/09/22 MiNK Therapeutics reports Q2 EPS (18c), consensus (24c) INCY Incyte $77.54 / -0.21 (-0.27%) 11/01/22 Incyte reports Q3 EPS 60c, consensus 72c 08/02/22 Incyte reports Q2 EPS $1.01, consensus 76c INBX Inhibrx $32.72 / +0.57 (+1.77%) 11/07/22 Inhibrx reports Q3 EPS (90c), consensus (94c) 08/08/22 Inhibrx reports Q2 EPS (97c), consensus (78c) GMAB Genmab $41.84 / -1.67 (-3.84%) 08/10/22 Genmab reports operating profit of DKK 1.761B for first half, up from DKK 1.32B 08/08/22 Genmab raises 2022 sales outlook to DKK 12B-13B from DKK 11B-12B FATE Fate Therapeutics $22.95 / +1.99 (+9.49%) 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) EXEL Exelixis $16.78 / -0.105 (-0.62%) 11/01/22 Exelixis sees FY22 revenue $1.575B-$1.6B, consensus $1.6B 11/01/22 Exelixis reports Q3 adjusted EPS 31c, consensus 19c 08/09/22 Exelixis reports Q2 EPS 28c, consensus 19c DNA Ginkgo Bioworks $2.86 / +0.225 (+8.56%) 08/15/22 Ginkgo Bioworks raises FY22 revenue view to $425M-$440M from $375M-$390M 08/15/22 Ginkgo Bioworks reports Q2 EPS (41c), consensus (4c) 05/16/22 Ginkgo Bioworks sees FY22 revenue view to $375M-$390M from $325M-$340M 05/16/22 Ginkgo Bioworks reports Q1 revenue $168M, consensus $105.68M CRL Charles River $246.43 / +8.49 (+3.57%) 11/02/22 Charles River sees Q4 adjusted EPS $2.65-$2.80, consensus $2.73 11/02/22 Charles River narrows FY22 adjusted EPS view to $10.80-$10.95, consensus $10.80 11/02/22 Charles River reports Q3 adjusted EPS $2.63, consensus $2.49 08/03/22 Charles River sees Q3 adjusted EPS down in high single digits vs. 3Q21 CLRB Cellectar Biosciences $1.90 / +0.01 (+0.53%) 11/03/22 Cellectar Biosciences reports Q3 EPS ($1.28), consensus ($1.21) 08/05/22 Cellectar Biosciences reports Q2 EPS ($1.22), consensus ($1.03) BMY Bristol-Myers $75.92 / -3.44 (-4.33%) 10/25/22 Notable companies reporting before tomorrow's open 10/25/22 Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51 10/25/22 Bristol-Myers reports Q3 EPS $1.99, consensus $1.83 ASND Ascendis Pharma $131.96 / +2.47 (+1.91%) 11/02/22 Ascendis Pharma reports Q3 EPS ( EUR 3.03) vs. (EUR 1.47) last year 08/10/22 Ascendis Pharma reports Q2 EPS EUR (1.46) vs EUR (2.50) last year AMGN Amgen $284.92 / -6.02 (-2.07%) 11/03/22 Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00 11/03/22 Amgen reports Q3 adjusted EPS $4.70, consensus $4.44 11/03/22 Notable companies reporting after market close 08/04/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.40 ALKS Alkermes $23.57 / -0.685 (-2.82%) 11/02/22 Alkermes raises FY22 adjusted EPS view to 15c-33c from 9c-27c, consensus 20c 11/02/22 Alkermes reports Q3 adjusted EPS 2c, consensus 3c 07/27/22 Alkermes raises FY22 adjusted EPS view to 9c-27c from (18c)-0c, consensus 4c 07/27/22 Alkermes reports Q2 adjusted EPS 6c, consensus 1c ADPT Adaptive Biotechnologies $9.32 / +0.23 (+2.53%) 11/03/22 Adaptive Biotechnologies narrows FY22 revenue view to $185M-$190M 11/03/22 Adaptive Biotechnologies reports Q3 EPS (32c), consensus (38c) 08/03/22 Adaptive Biotechnologiesbacks FY22 revenue $185M-$195M, consensus $187.62M 08/03/22 Adaptive Biotechnologies reports Q2 EPS (37c), consensus (43c) ABMD Abiomed $373.89 / +1.235 (+0.33%) 11/01/22 Abiomed reports Q2 EPS $1.30, consensus $1.04 TMO SGEN REGN MRK LH BMY AMGN TMO Thermo Fisher $539.07 / +18.83 (+3.62%) 10/30/22 Thermo Fisher said to near $2.3B deal for Binding Site, Bloomberg reports SGEN Seagen $132.82 / +1.77 (+1.35%) 08/26/22 Merck's Seagen bid hit snag over price concerns, Bloomberg reports 08/25/22 Merck's bid for Seagen stalled on price concerns, Bloomberg reports 07/15/22 Merck deal for Seagen unlikely to be completed by earnings, WSJ reports 07/07/22 Merck offers around $200 per share for Seagen, FT reports REGN Regeneron $734.49 / -7.28 (-0.98%) 09/16/22 WHO panel recommends against GSK, Regeneron COVID drugs, Bloomberg reports MRK Merck $97.90 / -3.91 (-3.84%) 10/07/22 Merck's Lagevrio sped COVID recovery, didn't lower hospital risk, STAT says LH Labcorp $249.20 / +6.07 (+2.50%) 07/28/22 LabCorp planning clinical development business unit spinoff, WSJ reports BMY Bristol-Myers $75.92 / -3.44 (-4.33%) 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 06/24/22 Judge says Bristol-Myers must face $6.4B Breyanzi lawsuit, Reuters says 06/14/22 FTC asked to investigate price hikes by Janssen, Bristol-Myers, STAT says 05/28/22 Buy Bristol-Myers, rally just getting started, Barron's says AMGN Amgen $284.92 / -6.02 (-2.07%) 11/04/22 Supreme Court to hear Amgen appeal in Repatha patent dispute, Bloomberg says 08/01/22 Amgen battles IRS over $10.7B in back taxes, WSJ reports XNCR VCYT TXG TMO TIL SGEN RHHBY REGN MRK LH IOVA INKT INCY INBX FATE EXEL DNA CUE CRL CGEN BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $29.42 / -1.07 (-3.51%) 09/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations VCYT Veracyte $29.95 / +1.915 (+6.83%) 11/07/22 Biotech Alert: Searches spiking for these stocks today 07/13/22 Fly Intel: After-Hours Movers TXG 10x Genomics $41.29 / +3.51 (+9.29%) 07/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/15/22 What You Missed On Wall Street On Friday 07/15/22 What You Missed On Wall Street This Morning 07/14/22 Fly Intel: After-Hours Movers TMO Thermo Fisher $539.07 / +18.83 (+3.62%) 10/31/22 What You Missed On Wall Street On Monday 10/31/22 What You Missed On Wall Street This Morning 10/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations TIL Instil Bio $2.26 / -0.16 (-6.63%) 10/31/22 Fly Intel: Pre-market Movers SGEN Seagen $132.82 / +1.77 (+1.35%) 10/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/26/22 What You Missed On Wall Street On Friday 08/26/22 What You Missed On Wall Street This Morning 07/18/22 What You Missed On Wall Street On Monday RHHBY Roche $43.25 / +0.72 (+1.69%) 10/24/22 Biotech Alert: Searches spiking for these stocks today 10/13/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/02/22 What You Missed On Wall Street This Morning REGN Regeneron $734.49 / -7.28 (-0.98%) 10/29/22 Buy/Sell: Wall Street's top 10 stock calls this week 10/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations MRK Merck $97.90 / -3.91 (-3.84%) 10/27/22 What You Missed On Wall Street On Thursday 10/27/22 What You Missed On Wall Street This Morning 10/27/22 Fly Intel: Pre-market Movers 10/20/22 Meet PDS Biotechnology: Fly exclusive interview with CEO Frank Bedu-Addo LH Labcorp $249.20 / +6.07 (+2.50%) 09/19/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/22/22 What You Missed On Wall Street On Monday 08/22/22 What You Missed On Wall Street This Morning 08/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations IOVA Iovance Biotherapeutics $8.87 / +0.205 (+2.37%) 05/27/22 What You Missed On Wall Street On Friday 05/27/22 What You Missed On Wall Street This Morning 05/26/22 Fly Intel: After-Hours Movers INKT MiNK Therapeutics $2.99 / +0.81 (+37.16%) 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations INCY Incyte $77.54 / -0.21 (-0.27%) 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/28/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations INBX Inhibrx $32.72 / +0.57 (+1.77%) 10/30/22 Sell these stocks now, proven algorithm says 10/04/22 What You Missed On Wall Street On Tuesday 10/04/22 What You Missed On Wall Street This Morning FATE Fate Therapeutics $22.95 / +1.99 (+9.49%) 11/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations EXEL Exelixis $16.78 / -0.105 (-0.62%) 10/04/22 Fly Intel: Pre-market Movers DNA Ginkgo Bioworks $2.86 / +0.225 (+8.56%) 10/05/22 Fly Intel: Pre-market Movers 08/16/22 What You Missed On Wall Street On Tuesday 08/16/22 What You Missed On Wall Street This Morning 08/16/22 Fly Intel: Pre-market Movers CUE Cue Biopharma $3.11 / +0.03 (+0.97%) 10/06/22 Biotech Alert: Searches spiking for these stocks today CRL Charles River $246.43 / +8.49 (+3.57%) 09/30/22 What You Missed On Wall Street On Friday 09/30/22 What You Missed On Wall Street This Morning 09/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CGEN Compugen / + 11/03/22 Biotech Alert: Searches spiking for these stocks today BMY Bristol-Myers $75.92 / -3.44 (-4.33%) 11/10/22 Meet Silo Pharma: Fly exclusive interview with CEO Weisblum, VP of R&D Kuo 10/26/22 What You Missed On Wall Street On Wednesday 10/26/22 What You Missed On Wall Street This Morning 10/26/22 Fly Intel: Pre-market Movers ASND Ascendis Pharma $131.96 / +2.47 (+1.91%) 10/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations AMGN Amgen $284.92 / -6.02 (-2.07%) 11/08/22 What You Missed On Wall Street On Tuesday 11/08/22 What You Missed On Wall Street This Morning 10/11/22 What You Missed On Wall Street On Tuesday 10/11/22 What You Missed On Wall Street This Morning ALKS Alkermes $23.57 / -0.685 (-2.82%) 11/03/22 What You Missed On Wall Street On Thursday 11/03/22 What You Missed On Wall Street This Morning 11/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ADPT Adaptive Biotechnologies $9.32 / +0.23 (+2.53%) 08/03/22 Fly Intel: After-Hours Movers ABMD Abiomed $373.89 / +1.235 (+0.33%) 11/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/01/22 What You Missed On Wall Street This Morning 11/01/22 Fly Intel: Pre-market Movers 11/12/22 ACR Convergence 2022 11/14/22 Data Science Virtual Conference 11/15/22 STAT Summit 2022 12/12/22 ASH Annual Meeting & Expo 2022 11/14/22 Compugen - CGEN 11/14/22 Cue Biopharma - CUE 11/14/22 Ginkgo Bioworks - DNA 11/21/22 Adaptive Biotechnologies - ADPT 02/02/23 Merck - MRK 02/02/23 Bristol-Myers - BMY 01/19/23 Tukysa (Tucatinib in combination with Trastuzumab) 01/29/23 PDUFA Date for new sBLA for KEYTRUDA 02/11/23 PDUFA Date for EYLEA (Aflibercept) Injection 02/28/23 PDUFA 06/16/23 PDUFA Date for CAMZYOS 11/18/22 Genmab 11/21/22 Adaptive Biotechnologies 11/22/22 Compugen 11/28/22 Compugen TMO SGEN REGN MRK IPSC IOVA DNA CRL BMY AMGN ABMD TMO Thermo Fisher $539.07 / +18.83 (+3.62%) 07/21/22 Early notable gainers among liquid option names on July 21st 07/20/22 Thermo Fisher call buyer realizes 52% same-day gains SGEN Seagen $132.82 / +1.77 (+1.35%) 07/28/22 Seattle Genetics options imply 5.8% move in share price post-earnings 07/07/22 Unusually active option classes on open July 7th REGN Regeneron $734.49 / -7.28 (-0.98%) 09/16/22 Early notable gainers among liquid option names on September 16th 09/09/22 Early notable gainers among liquid option names on September 9th 09/08/22 Early notable gainers among liquid option names on September 8th 08/03/22 Early notable gainers among liquid option names on August 3rd MRK Merck $97.90 / -3.91 (-3.84%) 10/10/22 Early notable gainers among liquid option names on October 10th 10/10/22 Unusually active option classes on open October 10th 09/22/22 Unusually active option classes on open September 22nd IPSC Century Therapeutics $10.95 / -0.64 (-5.52%) 06/15/22 Nineteen new option listings on June 15th IOVA Iovance Biotherapeutics $8.87 / +0.205 (+2.37%) 06/27/22 Iovance Biotherapeutics call volume above normal and directionally bullish 06/03/22 Iovance Biotherapeutics call volume above normal and directionally bullish DNA Ginkgo Bioworks $2.86 / +0.225 (+8.56%) 09/22/22 Largest borrow rate increases among liquid names 09/20/22 Largest borrow rate increases among liquid names 09/12/22 Largest borrow rate increases among liquid names 09/08/22 Largest borrow rate increases among liquid names CRL Charles River $246.43 / +8.49 (+3.57%) 11/02/22 Early notable gainers among liquid option names on November 2nd 10/25/22 Early notable gainers among liquid option names on October 25th 09/30/22 Early notable gainers among liquid option names on September 30th BMY Bristol-Myers $75.92 / -3.44 (-4.33%) 09/29/22 Early notable gainers among liquid option names on September 29th 09/12/22 Early notable gainers among liquid option names on September 12th 09/12/22 Unusually active option classes on open September 12th 09/08/22 Notable open interest changes for September 8th AMGN Amgen $284.92 / -6.02 (-2.07%) 10/11/22 Early notable gainers among liquid option names on October 11th 07/12/22 Amgen put volume heavy and directionally bearish 06/27/22 Amgen put volume heavy and directionally bearish ABMD Abiomed $373.89 / +1.235 (+0.33%) 11/01/22 Early notable gainers among liquid option names on November 1st
Conference/Events	Society for Immunotherapy of Cancer to hold a meeting » 04:55 11/11/22 11/11 04:55 11/11/22 04:55 ABMD Abiomed $372.72 / -1.39 (-0.37%) , ADPT Adaptive Biotechnologies $9.08 / +1.835 (+25.33%) , ALKS Alkermes $24.26 / +0.555 (+2.34%) , AMGN Amgen $290.96 / +1.37 (+0.47%) , ASND Ascendis Pharma $129.33 / +7.79 (+6.41%) , BMY Bristol-Myers $79.36 / -0.41 (-0.51%) , CGEN Compugen / + , CLRB Cellectar Biosciences $1.89 / + (+0.00%) , CRL Charles River $237.76 / +16.28 (+7.35%) , INKT MiNK Therapeutics $2.17 / -0.33 (-13.20%) , INCY Incyte $77.74 / +0.495 (+0.64%) , PHIO Phio Pharmaceuticals / + , INBX Inhibrx $32.21 / +3.15 (+10.84%) , XNCR Xencor $30.50 / +0.975 (+3.30%) , VCYT Veracyte $27.97 / +4.865 (+21.06%) , TXG 10x Genomics $37.82 / +7.41 (+24.37%) , TPST Tempest Therapeutics $1.55 / +0.03 (+1.97%) , TMO Thermo Fisher $520.24 / +35.69 (+7.37%) , TIL Instil Bio $2.42 / +0.1 (+4.32%) , SGEN Seagen $131.09 / -6.965 (-5.05%) , REGN Regeneron $740.63 / -2.855 (-0.38%) , REPL Replimune Group $20.12 / +2.19 (+12.21%) , RHHBY Roche $42.53 / +1.17 (+2.83%) , DNA Ginkgo Bioworks $2.64 / +0.345 (+15.07%) , CUE Cue Biopharma $3.11 / +0.18 (+6.14%) , IOVA Iovance Biotherapeutics $8.66 / +0.82 (+10.46%) , IPSC Century Therapeutics $11.59 / +1.54 (+15.32%) , LH Labcorp $243.13 / +12.6 (+5.47%) , MRK Merck $101.81 / +0.17 (+0.17%) , MXCT MaxCyte $7.05 / +0.995 (+16.45%) , EXEL Exelixis $16.89 / +0.5 (+3.05%) , FATE Fate Therapeutics $21.00 / +2.22 (+11.82%) , GMAB Genmab $43.53 / +2.23 (+5.40%) 37th Annual Meeting SITC… 37th Annual Meeting SITC 2022 to be held in Boston on November 8-12. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options XNCR VCYT TXG TPST TMO TIL SGEN RHHBY REPL REGN PHIO MXCT MRK LH IPSC IOVA INKT INCY INBX GMAB FATE EXEL DNA CUE CRL CLRB CGEN BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $30.50 / +0.975 (+3.30%) 10/20/22 SpikImm enters non-exclusive in-license agreement with Xencor 08/02/22 Xencor enters multi-year option, license agreement with Caris Life Sciences 05/26/22 Xencor reports initial dose-escalation Phase 1 data of XmAb 104 VCYT Veracyte $27.97 / +4.865 (+21.06%) 10/17/22 Exagen appoints John Aballi as CEO 09/22/22 Veracyte announces VANDAAM trial data published in journal 09/11/22 Veracyte announces new data from Phase 3 of STAMPEDE platform protocol 09/07/22 Veracyte's Envisia Genomic Classifier may predict lung disease progression TXG 10x Genomics $37.82 / +7.41 (+24.37%) 11/03/22 10x Genomics trading resumes 11/03/22 10x Genomics trading halted, volatility trading pause 08/02/22 Singular Genomics appoints Ropp as Chief Commercial Officer 07/14/22 10x Genomics drops 17% to $36.00 after Q2 revenue guidance misses estimates TPST Tempest Therapeutics $1.55 / +0.03 (+1.97%) 11/10/22 Tempest Therapeutics presents data on TPST-1120 10/06/22 Tempest Therapeutics to present on TREX1 at Emerging Technologies summit 08/15/22 Tempest Therapeutics announces near-term milestones 08/15/22 Tempest Therapeutics sees cash runway into 1Q24 TMO Thermo Fisher $520.24 / +35.69 (+7.37%) 11/10/22 Thermo Fisher authorizes $4B in share repurchases 10/31/22 Cytek Biosciences appoints Chris Williams as COO 10/31/22 Thermo Fisher announces $1B share repurchase program for Q4 10/31/22 Thermo Fisher to acquire The Binding Site Group for $2.6B in accretive deal TIL Instil Bio $2.42 / +0.1 (+4.32%) 11/08/22 Instil Bio announces poster presentations of CoSTAR platform 10/31/22 Instil Bio announces voluntary pause of enrollment in ongoing trials 10/18/22 Instil Bio announces first patient dosed with ITIL-306 09/06/22 Instil Bio appoints Tim Moore as COO SGEN Seagen $131.09 / -6.965 (-5.05%) 11/10/22 Seagen announces FDA approval for Adcetris in new indication 11/10/22 Seagen appoints David Epstein as CEO 09/27/22 Seagen, Zai Lab enter regional collaboration, license agreement for TIVDAK 09/27/22 Seagen to be paid $30M up-front in Zai Lab deal for Tivdak development in China RHHBY Roche $42.53 / +1.17 (+2.83%) 11/10/22 Oncolytics' pelareorep shows 69% response rate in pancreatic cancer study 11/09/22 Roche announces publication of STRONG-HF study 11/07/22 Oncolytics reports interim results from Phase 1/2 GOBLET study 10/27/22 Genentech announces both BALATON, COMINO trials met primary endpoint REPL Replimune Group $20.12 / +2.19 (+12.21%) 11/03/22 Replimune Group: Financing extends cash runway into 2025 10/07/22 Replimune Group secures $200M debt financing from Hercules Capital 08/04/22 Replimune Group expects cash to fund operations into 2H of 2024 06/28/22 Revolution Medicines announces election of Patel to board of directors REGN Regeneron $740.63 / -2.855 (-0.38%) 11/09/22 USPTO board says Mylan has shown claims of Regeneron patent 'unpatentable' 11/08/22 Regeneron: FDA approves Libtayo in combination with platinum-based chemotherapy 11/06/22 Intellia presents interim data from cardiomyopathy arm of Phase 1 study of '2001 11/03/22 Regeneron sees FY22 gross margin on net product sales 92.5%-93% PHIO Phio Pharmaceuticals / + 09/22/22 Phio Pharmaceuticals' PH-894 shows increased T-cell persistence 06/06/22 Phio Pharmaceuticals presents outline for first study of PH-762 for melanoma 05/16/22 Phio Pharmaceuticals' PH-894 shows enhanced HER2-CAR-T cell activity MXCT MaxCyte $7.05 / +0.995 (+16.45%) 09/28/22 MaxCyte signs strategic platform license with Vertex Pharmaceuticals 09/21/22 MaxCyte debuts new headquarters in Maryland's I-270 Biotech Corridor 07/12/22 MaxCyte signs strategic platform with LG Chem MRK Merck $101.81 / +0.17 (+0.17%) 11/10/22 Immutep announces clinical results from Phase II trial of eftilagimod alpha 11/10/22 Nektar's NKTR-288 shows enhanced anti-tumor activity in 11/10/22 Sellas Life Sciences announces data from its Phase 1/2 trial of galinpepimut-S LH Labcorp $243.13 / +12.6 (+5.47%) 10/13/22 Labcorp appoints Google Cloud exec Kliphouse to board of directors 08/23/22 Labcorp closes acquisition of RWJBarnabas Health outreach laboratory business 08/15/22 JANA Partners exits Zendesk, boosts stake in New Relic 08/09/22 Becton Dickinson, Labcorp announce CDx collaboration agreement IPSC Century Therapeutics $11.59 / +1.54 (+15.32%) 11/10/22 Century Therapeutics sees cash runway into 2025 10/03/22 Century Therapeutics appoints Daphne Quimi, Timothy Walbert to board 08/25/22 Century Therapeutics receives Study May Proceed notification for CNTY-101 08/11/22 Century Therapeutics expects cash to fund operations into 2025 IOVA Iovance Biotherapeutics $8.66 / +0.82 (+10.46%) 11/10/22 Iovance Biotherapeutics announces updated clinical data for lifileucel 11/07/22 Iovance Biotherapeutics announces updated clinical data for Lifileucel 10/10/22 Iovance Biotherapeutics doses first patient with PD-1 inactivated TIL therapy 08/25/22 Iovance Biotherapeutics initiates BLA submission for lifileucel INKT MiNK Therapeutics $2.17 / -0.33 (-13.20%) 11/10/22 MiNK Therapeutics presents clinical data at SITC 2022 INCY Incyte $77.74 / +0.495 (+0.64%) 11/07/22 Incyte, Mirati Therapeutics enter INCB99280 clinical trial and supply pact 10/19/22 Incyte's ruxolitinib cream shows repigmentation efficacy in Phase 3 trial 10/12/22 BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate 10/12/22 BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate INBX Inhibrx $32.21 / +3.15 (+10.84%) 10/04/22 Inhibrx announce potential to pursue accelerated approval in U.S. for INBRX-101 08/15/22 Inhibrx: EMA grants orphan drug designation to INBRX-109 06/30/22 Inhibrx completes Phase 1 dose escalation for INBRX-105, draws $60M loan 05/16/22 Inhibrx's INBRX-101 shows favorable safety profile in Phase 1 AATD trial GMAB Genmab $43.53 / +2.23 (+5.40%) 10/28/22 Genmab submits subcutaneous epcoritamab BLA to FDA 10/28/22 AbbVie: EMA validates MAA for epcoritamab 10/18/22 Genmab reports Q3 worldwide net sales of DARZALEX $2.05B FATE Fate Therapeutics $21.00 / +2.22 (+11.82%) 11/07/22 Fate announces exercise by ONO of option to FT825/ONO-8250 08/11/22 Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today 08/09/22 Fate Therapeutics announces preclinical study results on iPSCs 06/30/22 Fate Therapeutics appoints Brian Powl Chief Commercial Officer EXEL Exelixis $16.89 / +0.5 (+3.05%) 11/01/22 Exelixis, Cybrexa establish exclusive collaboration 11/01/22 Exelixis, Sairopa establish development collaboration, option agreement 10/26/22 Exelixis announces initial results from dose-escalation stage of JEWEL-101 10/04/22 Exelixis expands pact with Bristol-Myers for STELLAR-002 trial with combos DNA Ginkgo Bioworks $2.64 / +0.345 (+15.07%) 10/25/22 Ginkgo Bioworks selected by Saudi Arabia for biotechnology initiatives 10/20/22 Ginkgo Bioworks collaborates with Bolt Threads for optimization of Mylo material 10/19/22 Ginkgo Bioworks completes acquisition of Zymergen 10/11/22 Cathie Wood's ARK reports 10.64% stake in Ginkgo Bioworks CUE Cue Biopharma $3.11 / +0.18 (+6.14%) 11/10/22 Cue Biopharma reports new data from ongoing Phase 1 trial of CUE-101 combo 10/04/22 Cue Biopharma's CUE-101 granted Fast Track designation for treatment of NSCC 09/07/22 Cue Biopharma to present at two September scientific conferences 08/22/22 Cue Biopharma doses 1st patient in CUE-102 study for Wilms' Tumor cancer CRL Charles River $237.76 / +16.28 (+7.35%) 11/07/22 Charles River expands CDMO facility in Memphis 11/02/22 Charles River rises 10.6% 11/02/22 Charles River: 'Well-positioned' to finish 2022 on strong note 11/02/22 Charles River to divest Avian Vaccine unit for $170M in cash plus payments CLRB Cellectar Biosciences $1.89 / + (+0.00%) 10/21/22 Cellectar announces concurrent registered direct, private placement offerings 09/22/22 Cellectar awarded $2M grant to expand Phase 1 study iopofosine I 131 09/13/22 Cellectar announces publication of data from its Phase 2 CLOVER-1 study 08/05/22 Cellectar Biosciences expects cash to fund operations into 3Q23 CGEN Compugen / + 11/07/22 Compugen's COM701 shows preliminary anti-tumor activity in MSS-CRC patients 11/03/22 Compugen announces receipt of Nasdaq delisting notice 09/12/22 Compugen names Alberto Sessa as CFO 08/24/22 Compugen awarded new patent from Japan Patent Office BMY Bristol-Myers $79.36 / -0.41 (-0.51%) 11/07/22 Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports 11/03/22 Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital 10/31/22 Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints 10/27/22 Obsidian Therapeutics announces extension of agreement with Bristol-Myers ASND Ascendis Pharma $129.33 / +7.79 (+6.41%) 10/31/22 Ascendis announces FDA accepted priority review of its NDA for TransCon PTH 10/03/22 Crinetics appoints Dana Pizzuti as CDO 10/03/22 Ascendis announces recommended Phase 2 dose for transcendIT-101 09/12/22 Ascendis Pharma announces new Week 110 data from Phase 2 PaTH Forward Trial AMGN Amgen $290.96 / +1.37 (+0.47%) 11/09/22 Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead 11/09/22 Arrowhead sells royalty interest in olpasiran to Royalty Pharma for $250M+ 11/07/22 Amgen presents new Repatha data at AHA 2022 11/06/22 Amgen presents end-of-treatment data from Phase 2 OCEAN(a)-DOSE study ALKS Alkermes $24.26 / +0.555 (+2.34%) 11/02/22 Alkermes announces plans to separate oncology business 10/16/22 Acorda announces $16.5M award, royalty/supply relief in AMPYRA arbitration case 10/07/22 Sarissa Capital reports 8.55% stake in Alkermes, may seek to boost stake 07/06/22 Sarissa to vote for Alkermes director slate, still seeks board seat ADPT Adaptive Biotechnologies $9.08 / +1.835 (+25.33%) 10/11/22 Adaptive Biotechnologies partners with Epic to increase access to MRD monitoring 08/25/22 Cathie Wood's ARK Investment bought 155.4K shares of Adaptive Biotech today 07/28/22 Adaptive Biotechnologies receives expanded Medicare coverage of clonoSEQ 06/15/22 Adaptive Biotechnologies launches T-Detect Lyme ABMD Abiomed $372.72 / -1.39 (-0.37%) 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 11/01/22 J&J: Abiomed acquisition has enterprise value of $16.6B 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 10/31/22 Abiomed announces Impella RP Flex with SmartAssist receives FDA PMA ABMD ADPT ALKS AMGN ASND BMY CGEN CLRB CRL INKT INCY PHIO INBX XNCR VCYT TXG TPST TMO TIL SGEN REGN REPL RHHBY DNA CUE IOVA IPSC LH MRK MXCT EXEL FATE GMAB ABMD Abiomed $372.72 / -1.39 (-0.37%) 11/02/22 Morgan Stanley Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/22 Deutsche Bank Abiomed downgraded to Hold from Buy at Deutsche Bank 11/01/22 William Blair Abiomed downgraded to Market Perform from Outperform at William Blair 11/01/22 Piper Sandler Abiomed downgraded to Neutral from Overweight at Piper Sandler ADPT Adaptive Biotechnologies $9.08 / +1.835 (+25.33%) 10/26/22 Piper Sandler Natera named top pick in minimal residual disease at Piper Sandler 10/26/22 Piper Sandler Adaptive price target lowered to $7.50 from $12 at Piper Sandler 08/24/22 Credit Suisse Adaptive Biotechnologies initiated with an Underperform at Credit Suisse 08/17/22 Piper Sandler Adaptive Biotechnologies price target raised to $12 from $7.50 at Piper Sandler ALKS Alkermes $24.26 / +0.555 (+2.34%) 11/03/22 Piper Sandler Alkermes upgraded to Overweight from Neutral at Piper Sandler 10/20/22 Mizuho Alkermes Q3 miss may be largely priced in, says Mizuho 10/19/22 Piper Sandler Alkermes shares have more downside risk, says Piper Sandler 10/14/22 BofA Alkermes upgraded to Neutral at BofA on improved risk/reward AMGN Amgen $290.96 / +1.37 (+0.47%) 11/08/22 Oppenheimer Amgen price target raised to $300 from $290 at Oppenheimer 11/08/22 Truist Amgen price target raised to $280 from $266 at Truist 11/04/22 Piper Sandler Amgen price target raised to $278 from $265 at Piper Sandler 10/31/22 Barclays Amgen downgraded to Underweight from Equal Weight at Barclays ASND Ascendis Pharma $129.33 / +7.79 (+6.41%) 11/03/22 Oppenheimer Ascendis Pharma price target raised to $150 from $144 at Oppenheimer 11/03/22 Wedbush Ascendis Pharma price target raised to $151 from $144 at Wedbush 11/03/22 Credit Suisse Ascendis Pharma price target raised to $130 from $123 at Credit Suisse 11/03/22 Citi Ascendis Pharma price target raised to $163 from $157 at Citi BMY Bristol-Myers $79.36 / -0.41 (-0.51%) 11/02/22 Evercore ISI Evercore starts Legend Biotech with an Outperform on Carvykti potential 10/31/22 Guggenheim 2seventy Bio initiated with a Buy at Guggenheim 10/12/22 Barclays Bristol-Myers price target lowered to $66 from $69 at Barclays 10/10/22 Guggenheim Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials CGEN Compugen / + 08/23/22 Truist Compugen price target lowered to $4 from $14 at Truist 08/08/22 JMP Securities Compugen price target lowered to $4 from $8 at JMP Securities 08/05/22 Jefferies Jefferies downgrades Compugen to Hold with cash likely becoming 'growing issue' 08/05/22 Jefferies Compugen downgraded to Hold from Buy at Jefferies CLRB Cellectar Biosciences $1.89 / + (+0.00%) 11/08/22 Maxim Cellectar Biosciences price target lowered to $7 from $12.50 at Maxim 11/04/22 Oppenheimer Cellectar Biosciences price target lowered to $12 from $47 at Oppenheimer 07/18/22 Oppenheimer Cellectar Biosciences assumed with an Outperform at Oppenheimer 04/07/22 Ladenburg Cellectar Biosciences transferred with a Buy at Ladenburg CRL Charles River $237.76 / +16.28 (+7.35%) 11/03/22 Credit Suisse Charles River price target lowered to $280 from $285 at Credit Suisse 09/30/22 Jefferies Charles River upgraded to Buy at Jefferies on nonhuman primate tailwinds 09/29/22 Jefferies Charles River upgraded to Buy from Hold at Jefferies 08/24/22 Credit Suisse Charles River initiated with an Outperform at Credit Suisse INKT MiNK Therapeutics $2.17 / -0.33 (-13.20%) 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright 05/11/22 B. Riley MiNK Therapeutics price target lowered to $7 from $10 at B. Riley 01/24/22 B. Riley MiNK Therapeutics price target lowered to $10 from $24 at B. Riley INCY Incyte $77.74 / +0.495 (+0.64%) 10/24/22 JPMorgan Incyte price target lowered to $80 from $86 at JPMorgan 08/03/22 Evercore ISI Incyte downgraded to In Line from Outperform at Evercore ISI 08/03/22 Guggenheim Incyte downgraded to Neutral at Guggenheim after Opzelura Q2 miss 08/03/22 Oppenheimer Incyte price target lowered to $98 from $109 at Oppenheimer PHIO Phio Pharmaceuticals / + INBX Inhibrx $32.21 / +3.15 (+10.84%) 10/05/22 Evercore ISI Inhibrx price target raised to $60 from $54 at Evercore ISI 08/09/22 Credit Suisse Inhibrx price target lowered to $48 from $53 at Credit Suisse 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko XNCR Xencor $30.50 / +0.975 (+3.30%) 11/09/22 Canaccord Xencor price target lowered to $48 from $50 at Canaccord 11/08/22 Raymond James Xencor added to Analyst Current Favorites list at Raymond James 10/13/22 Raymond James Xencor upgraded to Strong Buy from Outperform at Raymond James 10/13/22 Raymond James Xencor upgraded to Strong Buy from Outperform at Raymond James VCYT Veracyte $27.97 / +4.865 (+21.06%) 05/04/22 Needham Veracyte price target lowered to $26 from $31 at Needham 03/15/22 Needham Needham drops Veracyte target, says shares undervalued 03/01/22 Lake Street Veracyte price target lowered to $50 from $95 at Lake Street 03/01/22 Needham Veracyte price target lowered to $35 from $55 at Needham TXG 10x Genomics $37.82 / +7.41 (+24.37%) 11/03/22 JPMorgan 10x Genomics price target lowered to $55 from $65 at JPMorgan 08/18/22 Goldman Sachs 10x Genomics downgraded to Sell from Neutral at Goldman Sachs 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler 08/10/22 Morgan Stanley 10x Genomics price target lowered to $70 from $100 at Morgan Stanley TPST Tempest Therapeutics $1.55 / +0.03 (+1.97%) 09/15/22 Ladenburg Tempest Therapeutics initiated with a Buy at Ladenburg 05/13/22 Piper Sandler Tempest Therapeutics price target lowered to $10 from $20 at Piper Sandler 05/13/22 H.C. Wainwright Tempest Therapeutics price target lowered to $35 from $51 at H.C. Wainwright 04/27/22 Piper Sandler Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20 TMO Thermo Fisher $520.24 / +35.69 (+7.37%) 11/01/22 Baird Thermo Fisher price target lowered to $665 from $695 at Baird 10/27/22 Morgan Stanley Thermo Fisher price target lowered to $613 from $678 at Morgan Stanley 10/27/22 Baird Thermo Fisher price target lowered to $696 from $711 at Baird 10/27/22 Citi Thermo Fisher price target lowered to $650 from $715 at Citi TIL Instil Bio $2.42 / +0.1 (+4.32%) 11/01/22 TD Cowen Cowen downgrades Instil Bio on manufacturing failures 11/01/22 Truist Instil Bio downgraded to Hold from Buy at Truist 11/01/22 Baird Instil Bio price target lowered to $24 from $31 at Baird 11/01/22 TD Cowen Instil Bio downgraded to Market Perform from Outperform at Cowen SGEN Seagen $131.09 / -6.965 (-5.05%) 10/28/22 Oppenheimer Seagen price target lowered to $188 from $208 at Oppenheimer 10/28/22 H.C. Wainwright Seagen price target lowered to $180 from $200 at H.C. Wainwright 10/24/22 JPMorgan Seagen price target lowered to $155 from $194 at JPMorgan 10/11/22 BMO Capital Seagen upgraded to Outperform from Market Perform at BMO Capital REGN Regeneron $740.63 / -2.855 (-0.38%) 11/09/22 RBC Capital Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital 11/09/22 Truist Regeneron price target raised to $856 from $790 at Truist 11/03/22 Piper Sandler Regeneron price target lowered to $765 from $775 at Piper Sandler 10/31/22 EF Hutton Regeneron initiated with a Buy at EF Hutton REPL Replimune Group $20.12 / +2.19 (+12.21%) 10/14/22 BMO Capital Replimune Group price target raised to $40 from $30 at BMO Capital 08/16/22 Piper Sandler Replimune Group price target lowered to $43 from $44 at Piper Sandler 05/24/22 Wedbush Replimune Group price target lowered to $52 from $59 at Wedbush 05/19/22 Piper Sandler Replimune Group price target lowered to $44 from $52 at Piper Sandler RHHBY Roche $42.53 / +1.17 (+2.83%) 10/25/22 Capital One Arvinas initiated with an Overweight at Capital One 10/17/22 Morgan Stanley Roche's AD drug expected to fall short in trial, says Morgan Stanley 10/12/22 Stifel Biogen upgraded to Buy from Hold at Stifel 10/11/22 Morgan Stanley Arcus Biosciences initiated with an Overweight at Morgan Stanley DNA Ginkgo Bioworks $2.64 / +0.345 (+15.07%) 10/04/22 Morgan Stanley Ginkgo Bioworks initiated with an Equal Weight at Morgan Stanley 08/16/22 BTIG Ginkgo Bioworks price target raised to $6 from $5 at BTIG 08/16/22 Raymond James Ginkgo Bioworks price target raised to $14.50 from $11.50 at Raymond James 07/26/22 William Blair Zymergen buyout deal 'best case scenario,' says William Blair CUE Cue Biopharma $3.11 / +0.18 (+6.14%) 11/10/22 Oppenheimer Cue Biopharma's SITC data a 'big improvement,' says Oppenheimer 08/24/22 Oppenheimer Cue Biopharma price target lowered to $10 from $26 at Oppenheimer 03/23/22 JMP Securities Cue Biopharma price target lowered to $15 from $30 at JMP Securities 03/21/22 Oppenheimer Cue Biopharma price target lowered to $26 from $32 at Oppenheimer IOVA Iovance Biotherapeutics $8.66 / +0.82 (+10.46%) 10/31/22 Guggenheim Iovance Biotherapeutics initiated with a Neutral at Guggenheim 08/18/22 Wells Fargo Iovance Biotherapeutics assumed with an Equal Weight at Wells Fargo 08/08/22 Stifel Global Blood Therapeutics downgraded to Hold from Buy at Stifel IPSC Century Therapeutics $11.59 / +1.54 (+15.32%) 10/31/22 Guggenheim Century Therapeutics initiated with a Buy at Guggenheim 10/10/22 Canaccord Century Therapeutics initiated with a Buy at Canaccord 06/10/22 Roth MKM Century Therapeutics initiated with a Buy at Roth Capital 05/23/22 H.C. Wainwright Century Therapeutics initiated with a Buy at H.C. Wainwright LH Labcorp $243.13 / +12.6 (+5.47%) 11/03/22 Mizuho Labcorp price target lowered to $250 from $296 at Mizuho 10/28/22 Citi Labcorp price target lowered to $275 from $300 at Citi 10/28/22 Baird Labcorp price target lowered to $270 from $297 at Baird 09/19/22 Argus Labcorp downgraded to Hold from Buy at Argus MRK Merck $101.81 / +0.17 (+0.17%) 11/01/22 Oppenheimer Merck pact shows Veeva life science vendor of choice, says Oppenheimer 11/01/22 Guggenheim Merck price target raised to $111 from $104 at Guggenheim 10/28/22 Morgan Stanley Merck price target raised to $100 from $91 at Morgan Stanley 10/28/22 Cantor Fitzgerald Merck price target raised to $120 from $107 at Cantor Fitzgerald MXCT MaxCyte $7.05 / +0.995 (+16.45%) 08/14/22 BTIG MaxCyte price target raised to $11 from $10 at BTIG EXEL Exelixis $16.89 / +0.5 (+3.05%) 11/02/22 TD Cowen Exelixis price target lowered to $21 from $26 at Cowen 10/31/22 EF Hutton Exelixis initiated with a Buy at EF Hutton 10/18/22 JMP Securities Exelixis initiated with an Outperform at JMP Securities 10/12/22 Guggenheim Initial data for Exelixis's XB002 show encouraging safety, says Guggenheim FATE Fate Therapeutics $21.00 / +2.22 (+11.82%) 11/04/22 Cantor Fitzgerald Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald 10/10/22 Canaccord Fate Therapeutics initiated with a Buy at Canaccord 08/18/22 Wells Fargo Fate Therapeutics assumed with an Overweight at Wells Fargo 08/04/22 Oppenheimer Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer GMAB Genmab $43.53 / +2.23 (+5.40%) 10/17/22 DNB Markets Genmab downgraded to Hold from Buy at DNB Markets 09/15/22 Credit Suisse Genmab price target raised to DKK 2,800 from DKK 2,600 at Credit Suisse 08/22/22 H.C. Wainwright Genmab price target raised to $51 from $49 at H.C. Wainwright 08/12/22 JPMorgan Genmab price target raised to DKK 2,900 from DKK 2,700 at JPMorgan XNCR VCYT TXG TPST TMO TIL SGEN RHHBY REPL REGN MXCT MRK LH IPSC IOVA INKT INCY INBX GMAB FATE EXEL DNA CRL CLRB BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $30.50 / +0.975 (+3.30%) 11/07/22 Xencor reports Q3 EPS (55c), consensus (68c) 08/03/22 Xencor reports Q2 EPS (57c), consensus (44c) VCYT Veracyte $27.97 / +4.865 (+21.06%) 11/02/22 Veracyte raises FY2 revenue view to $288M-$293M from $272M-$280M 11/02/22 Veracyte reports Q3 EPS (12c), consensus (25c) 08/02/22 Veracyte raises FY22 revenue view to $272M-$280M, consensus $272.42M 08/02/22 Veracyte reports Q2 EPS (13c), consensus (22c) TXG 10x Genomics $37.82 / +7.41 (+24.37%) 11/02/22 10x Genomics sees 2022 revenue $500M-$522M, consensus $509.87M 11/02/22 10x Genomics reports Q3 EPS (37c), consensus (46c) 08/08/22 10x Genomics updated FY22 revenue view to $500M-$520M, consensus $571.06M 08/08/22 10x Genomics reports Q2 EPS (57c), consensus (39c) TPST Tempest Therapeutics $1.55 / +0.03 (+1.97%) 11/08/22 Tempest Therapeutics reports Q3 EPS (66c), consensus (80c) 08/15/22 Tempest Therapeutics reports Q2 EPs (79c) vs. ($7.63) last year. 05/13/22 Tempest Therapeutics reports Q1 EPS ($1.18), consensus ($1.12) TMO Thermo Fisher $520.24 / +35.69 (+7.37%) 10/26/22 Thermo Fisher raises FY22 EPS view to $23.01 from $22.93, consensus $22.95 10/26/22 Thermo Fisher reports Q3 adjusted EPS $5.08, consensus $4.82 TIL Instil Bio $2.42 / +0.1 (+4.32%) 08/12/22 Instil Bio reports Q2 adjusted EPS (40c), consensus (41c) 05/16/22 Instil Bio reports Q1 EPS (42c), consensus (38c) SGEN Seagen $131.09 / -6.965 (-5.05%) 10/27/22 Seagen raises FY22 revenue $1.82B-$1.865B from $1.71B-$1.795B 10/27/22 Seagen reports Q3 EPS ($1.03), consensus (95c) 07/28/22 Seagen raises FY22 revenue view to $1.71B-$1.795B from $1.665B-$1.745B 07/28/22 Seagen reports Q2 EPS (73c), consensus (86c) RHHBY Roche $42.53 / +1.17 (+2.83%) 10/18/22 Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year 07/21/22 Roche reports 1H core EPS CHF 11.76 vs. CHF 10.56 last year REPL Replimune Group $20.12 / +2.19 (+12.21%) 11/03/22 Replimune Group reports Q2 EPS (79c), consensus (78c) 08/04/22 Replimune Group reports Q1 EPS (78c) vs (53c) last year 05/19/22 Replimune Group reports 2022 EPS ($2.26), consensus ($2.26) REGN Regeneron $740.63 / -2.855 (-0.38%) 11/03/22 Regeneron reports Q3 EPS $11.14, consensus $9.48 11/02/22 Notable companies reporting before tomorrow's open 08/03/22 Regeneron reports Q2 EPS $9.77, consensus $9.54 MXCT MaxCyte $7.05 / +0.995 (+16.45%) 11/09/22 MaxCyte reports Q3 EPS (6c) consensus (9c) 08/10/22 MaxCyte sees FY22 core business revenue growth of 30% year-over-year 08/10/22 MaxCyte reports Q2 EPS (8c), consensus (8c) MRK Merck $101.81 / +0.17 (+0.17%) 10/27/22 Merck raises FY22 adjusted EPS view to $7.32-$7.37 from $7.25-$7.35 10/27/22 Merck reports Q3 adjusted EPS $1.85, consensus $1.71 10/26/22 Notable companies reporting before tomorrow's open LH Labcorp $243.13 / +12.6 (+5.47%) 10/27/22 Labcorp sees FY22 EPS $19.25- $20.25 , consensus $20.19 10/27/22 Labcorp reports Q3 EPS $4.68, consensus $4.67 07/28/22 LabCorp raises FY22 adjusted EPS view to $19.00-$21.25 from $18.25-$21.00 07/28/22 LabCorp reports Q2 adjusted EPS $4.96, consensus $4.70 IPSC Century Therapeutics $11.59 / +1.54 (+15.32%) 11/10/22 Century Therapeutics reports Q3 EPS (53c), consensus (59c) 08/11/22 Century Therapeutics reports Q2 EPS (54c), consensus (52c) 05/16/22 Century Therapeutics reports Q1 EPS (66c), consensus (45c) IOVA Iovance Biotherapeutics $8.66 / +0.82 (+10.46%) 11/03/22 Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c) 08/04/22 Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c) INKT MiNK Therapeutics $2.17 / -0.33 (-13.20%) 11/03/22 MiNK Therapeutics reports Q3 EPS (19c), consensus (23c) 08/09/22 MiNK Therapeutics reports Q2 EPS (18c), consensus (24c) INCY Incyte $77.74 / +0.495 (+0.64%) 11/01/22 Incyte reports Q3 EPS 60c, consensus 72c 08/02/22 Incyte reports Q2 EPS $1.01, consensus 76c INBX Inhibrx $32.21 / +3.15 (+10.84%) 11/07/22 Inhibrx reports Q3 EPS (90c), consensus (94c) 08/08/22 Inhibrx reports Q2 EPS (97c), consensus (78c) GMAB Genmab $43.53 / +2.23 (+5.40%) 08/10/22 Genmab reports operating profit of DKK 1.761B for first half, up from DKK 1.32B 08/08/22 Genmab raises 2022 sales outlook to DKK 12B-13B from DKK 11B-12B 05/11/22 Genmab narrows 2022 revenue view DKK 11B - DKK 12B from DKK 10.8B - DKK 12B 05/11/22 Genmab reports Q1 revenue DKK 2.1B vs. DKK 1.58B last year FATE Fate Therapeutics $21.00 / +2.22 (+11.82%) 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) EXEL Exelixis $16.89 / +0.5 (+3.05%) 11/01/22 Exelixis sees FY22 revenue $1.575B-$1.6B, consensus $1.6B 11/01/22 Exelixis reports Q3 adjusted EPS 31c, consensus 19c 08/09/22 Exelixis reports Q2 EPS 28c, consensus 19c DNA Ginkgo Bioworks $2.64 / +0.345 (+15.07%) 08/15/22 Ginkgo Bioworks raises FY22 revenue view to $425M-$440M from $375M-$390M 08/15/22 Ginkgo Bioworks reports Q2 EPS (41c), consensus (4c) 05/16/22 Ginkgo Bioworks sees FY22 revenue view to $375M-$390M from $325M-$340M 05/16/22 Ginkgo Bioworks reports Q1 revenue $168M, consensus $105.68M CRL Charles River $237.76 / +16.28 (+7.35%) 11/02/22 Charles River sees Q4 adjusted EPS $2.65-$2.80, consensus $2.73 11/02/22 Charles River narrows FY22 adjusted EPS view to $10.80-$10.95, consensus $10.80 11/02/22 Charles River reports Q3 adjusted EPS $2.63, consensus $2.49 08/03/22 Charles River sees Q3 adjusted EPS down in high single digits vs. 3Q21 CLRB Cellectar Biosciences $1.89 / + (+0.00%) 11/03/22 Cellectar Biosciences reports Q3 EPS ($1.28), consensus ($1.21) 08/05/22 Cellectar Biosciences reports Q2 EPS ($1.22), consensus ($1.03) BMY Bristol-Myers $79.36 / -0.41 (-0.51%) 10/25/22 Notable companies reporting before tomorrow's open 10/25/22 Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51 10/25/22 Bristol-Myers reports Q3 EPS $1.99, consensus $1.83 ASND Ascendis Pharma $129.33 / +7.79 (+6.41%) 11/02/22 Ascendis Pharma reports Q3 EPS ( EUR 3.03) vs. (EUR 1.47) last year 08/10/22 Ascendis Pharma reports Q2 EPS EUR (1.46) vs EUR (2.50) last year 05/11/22 Ascendis Pharma reports Q1 EPS EUR (2.21) vs. EUR (1.17) AMGN Amgen $290.96 / +1.37 (+0.47%) 11/03/22 Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00 11/03/22 Amgen reports Q3 adjusted EPS $4.70, consensus $4.44 11/03/22 Notable companies reporting after market close 08/04/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.40 ALKS Alkermes $24.26 / +0.555 (+2.34%) 11/02/22 Alkermes raises FY22 adjusted EPS view to 15c-33c from 9c-27c, consensus 20c 11/02/22 Alkermes reports Q3 adjusted EPS 2c, consensus 3c 07/27/22 Alkermes raises FY22 adjusted EPS view to 9c-27c from (18c)-0c, consensus 4c 07/27/22 Alkermes reports Q2 adjusted EPS 6c, consensus 1c ADPT Adaptive Biotechnologies $9.08 / +1.835 (+25.33%) 11/03/22 Adaptive Biotechnologies narrows FY22 revenue view to $185M-$190M 11/03/22 Adaptive Biotechnologies reports Q3 EPS (32c), consensus (38c) 08/03/22 Adaptive Biotechnologiesbacks FY22 revenue $185M-$195M, consensus $187.62M 08/03/22 Adaptive Biotechnologies reports Q2 EPS (37c), consensus (43c) ABMD Abiomed $372.72 / -1.39 (-0.37%) 11/01/22 Abiomed reports Q2 EPS $1.30, consensus $1.04 TMO SGEN REGN MRK LH BMY AMGN TMO Thermo Fisher $520.24 / +35.69 (+7.37%) 10/30/22 Thermo Fisher said to near $2.3B deal for Binding Site, Bloomberg reports SGEN Seagen $131.09 / -6.965 (-5.05%) 08/26/22 Merck's Seagen bid hit snag over price concerns, Bloomberg reports 08/25/22 Merck's bid for Seagen stalled on price concerns, Bloomberg reports 07/15/22 Merck deal for Seagen unlikely to be completed by earnings, WSJ reports 07/07/22 Merck offers around $200 per share for Seagen, FT reports REGN Regeneron $740.63 / -2.855 (-0.38%) 09/16/22 WHO panel recommends against GSK, Regeneron COVID drugs, Bloomberg reports MRK Merck $101.81 / +0.17 (+0.17%) 10/07/22 Merck's Lagevrio sped COVID recovery, didn't lower hospital risk, STAT says LH Labcorp $243.13 / +12.6 (+5.47%) 07/28/22 LabCorp planning clinical development business unit spinoff, WSJ reports BMY Bristol-Myers $79.36 / -0.41 (-0.51%) 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 06/24/22 Judge says Bristol-Myers must face $6.4B Breyanzi lawsuit, Reuters says 06/14/22 FTC asked to investigate price hikes by Janssen, Bristol-Myers, STAT says 05/28/22 Buy Bristol-Myers, rally just getting started, Barron's says AMGN Amgen $290.96 / +1.37 (+0.47%) 11/04/22 Supreme Court to hear Amgen appeal in Repatha patent dispute, Bloomberg says 08/01/22 Amgen battles IRS over $10.7B in back taxes, WSJ reports XNCR VCYT TXG TMO TIL SGEN RHHBY REGN MRK LH IOVA INKT INCY INBX FATE EXEL DNA CUE CRL CGEN BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $30.50 / +0.975 (+3.30%) 09/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations VCYT Veracyte $27.97 / +4.865 (+21.06%) 11/07/22 Biotech Alert: Searches spiking for these stocks today 07/13/22 Fly Intel: After-Hours Movers TXG 10x Genomics $37.82 / +7.41 (+24.37%) 07/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/15/22 What You Missed On Wall Street On Friday 07/15/22 What You Missed On Wall Street This Morning 07/14/22 Fly Intel: After-Hours Movers TMO Thermo Fisher $520.24 / +35.69 (+7.37%) 10/31/22 What You Missed On Wall Street On Monday 10/31/22 What You Missed On Wall Street This Morning 10/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations TIL Instil Bio $2.42 / +0.1 (+4.32%) 10/31/22 Fly Intel: Pre-market Movers SGEN Seagen $131.09 / -6.965 (-5.05%) 10/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/26/22 What You Missed On Wall Street On Friday 08/26/22 What You Missed On Wall Street This Morning 07/18/22 What You Missed On Wall Street On Monday RHHBY Roche $42.53 / +1.17 (+2.83%) 10/24/22 Biotech Alert: Searches spiking for these stocks today 10/13/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/02/22 What You Missed On Wall Street This Morning REGN Regeneron $740.63 / -2.855 (-0.38%) 10/29/22 Buy/Sell: Wall Street's top 10 stock calls this week 10/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations MRK Merck $101.81 / +0.17 (+0.17%) 10/27/22 What You Missed On Wall Street On Thursday 10/27/22 What You Missed On Wall Street This Morning 10/27/22 Fly Intel: Pre-market Movers 10/20/22 Meet PDS Biotechnology: Fly exclusive interview with CEO Frank Bedu-Addo LH Labcorp $243.13 / +12.6 (+5.47%) 09/19/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/22/22 What You Missed On Wall Street On Monday 08/22/22 What You Missed On Wall Street This Morning 08/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations IOVA Iovance Biotherapeutics $8.66 / +0.82 (+10.46%) 05/27/22 What You Missed On Wall Street On Friday 05/27/22 What You Missed On Wall Street This Morning 05/26/22 Fly Intel: After-Hours Movers INKT MiNK Therapeutics $2.17 / -0.33 (-13.20%) 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations INCY Incyte $77.74 / +0.495 (+0.64%) 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/28/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations INBX Inhibrx $32.21 / +3.15 (+10.84%) 10/30/22 Sell these stocks now, proven algorithm says 10/04/22 What You Missed On Wall Street On Tuesday 10/04/22 What You Missed On Wall Street This Morning FATE Fate Therapeutics $21.00 / +2.22 (+11.82%) 11/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations EXEL Exelixis $16.89 / +0.5 (+3.05%) 10/04/22 Fly Intel: Pre-market Movers DNA Ginkgo Bioworks $2.64 / +0.345 (+15.07%) 10/05/22 Fly Intel: Pre-market Movers 08/16/22 What You Missed On Wall Street On Tuesday 08/16/22 What You Missed On Wall Street This Morning 08/16/22 Fly Intel: Pre-market Movers CUE Cue Biopharma $3.11 / +0.18 (+6.14%) 10/06/22 Biotech Alert: Searches spiking for these stocks today CRL Charles River $237.76 / +16.28 (+7.35%) 09/30/22 What You Missed On Wall Street On Friday 09/30/22 What You Missed On Wall Street This Morning 09/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CGEN Compugen / + 11/03/22 Biotech Alert: Searches spiking for these stocks today BMY Bristol-Myers $79.36 / -0.41 (-0.51%) 11/10/22 Meet Silo Pharma: Fly exclusive interview with CEO Weisblum, VP of R&D Kuo 10/26/22 What You Missed On Wall Street On Wednesday 10/26/22 What You Missed On Wall Street This Morning 10/26/22 Fly Intel: Pre-market Movers ASND Ascendis Pharma $129.33 / +7.79 (+6.41%) 10/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations AMGN Amgen $290.96 / +1.37 (+0.47%) 11/08/22 What You Missed On Wall Street On Tuesday 11/08/22 What You Missed On Wall Street This Morning 10/11/22 What You Missed On Wall Street On Tuesday 10/11/22 What You Missed On Wall Street This Morning ALKS Alkermes $24.26 / +0.555 (+2.34%) 11/03/22 What You Missed On Wall Street On Thursday 11/03/22 What You Missed On Wall Street This Morning 11/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ADPT Adaptive Biotechnologies $9.08 / +1.835 (+25.33%) 08/03/22 Fly Intel: After-Hours Movers ABMD Abiomed $372.72 / -1.39 (-0.37%) 11/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/01/22 What You Missed On Wall Street This Morning 11/01/22 Fly Intel: Pre-market Movers 11/11/22 6th Annual IO Next Virtual Summit 11/12/22 ACR Convergence 2022 11/14/22 Data Science Virtual Conference 11/15/22 STAT Summit 2022 12/12/22 ASH Annual Meeting & Expo 2022 11/14/22 Compugen - CGEN 11/14/22 Cue Biopharma - CUE 11/14/22 Ginkgo Bioworks - DNA 11/21/22 Adaptive Biotechnologies - ADPT 02/02/23 Merck - MRK 02/02/23 Bristol-Myers - BMY 01/19/23 Tukysa (Tucatinib in combination with Trastuzumab) 01/29/23 PDUFA Date for new sBLA for KEYTRUDA 02/11/23 PDUFA Date for EYLEA (Aflibercept) Injection 02/28/23 PDUFA 06/16/23 PDUFA Date for CAMZYOS 11/18/22 Genmab 11/21/22 Adaptive Biotechnologies 11/22/22 Compugen 11/28/22 Compugen TMO SGEN REGN MRK IPSC IOVA DNA CRL BMY AMGN ABMD TMO Thermo Fisher $520.24 / +35.69 (+7.37%) 07/21/22 Early notable gainers among liquid option names on July 21st 07/20/22 Thermo Fisher call buyer realizes 52% same-day gains SGEN Seagen $131.09 / -6.965 (-5.05%) 07/28/22 Seattle Genetics options imply 5.8% move in share price post-earnings 07/07/22 Unusually active option classes on open July 7th REGN Regeneron $740.63 / -2.855 (-0.38%) 09/16/22 Early notable gainers among liquid option names on September 16th 09/09/22 Early notable gainers among liquid option names on September 9th 09/08/22 Early notable gainers among liquid option names on September 8th 08/03/22 Early notable gainers among liquid option names on August 3rd MRK Merck $101.81 / +0.17 (+0.17%) 10/10/22 Early notable gainers among liquid option names on October 10th 10/10/22 Unusually active option classes on open October 10th 09/22/22 Unusually active option classes on open September 22nd IPSC Century Therapeutics $11.59 / +1.54 (+15.32%) 06/15/22 Nineteen new option listings on June 15th IOVA Iovance Biotherapeutics $8.66 / +0.82 (+10.46%) 06/27/22 Iovance Biotherapeutics call volume above normal and directionally bullish 06/03/22 Iovance Biotherapeutics call volume above normal and directionally bullish DNA Ginkgo Bioworks $2.64 / +0.345 (+15.07%) 09/22/22 Largest borrow rate increases among liquid names 09/20/22 Largest borrow rate increases among liquid names 09/12/22 Largest borrow rate increases among liquid names 09/08/22 Largest borrow rate increases among liquid names CRL Charles River $237.76 / +16.28 (+7.35%) 11/02/22 Early notable gainers among liquid option names on November 2nd 10/25/22 Early notable gainers among liquid option names on October 25th 09/30/22 Early notable gainers among liquid option names on September 30th BMY Bristol-Myers $79.36 / -0.41 (-0.51%) 09/29/22 Early notable gainers among liquid option names on September 29th 09/12/22 Early notable gainers among liquid option names on September 12th 09/12/22 Unusually active option classes on open September 12th 09/08/22 Notable open interest changes for September 8th AMGN Amgen $290.96 / +1.37 (+0.47%) 10/11/22 Early notable gainers among liquid option names on October 11th 07/12/22 Amgen put volume heavy and directionally bearish 06/27/22 Amgen put volume heavy and directionally bearish ABMD Abiomed $372.72 / -1.39 (-0.37%) 11/01/22 Early notable gainers among liquid option names on November 1st
Hot Stocks	MiNK Therapeutics presents clinical data at SITC 2022 » 09:33 11/10/22 11/10 09:33 11/10/22 09:33 INKT MiNK Therapeutics $2.49 / -0.06 (-2.35%) MiNK Therapeutics… MiNK Therapeutics announced the presentation of new data from five presentations at the 2022 Society for Immunotherapy of Cancer, SITC, Annual Meeting. "Allogeneic unmodified iNKTs show reductions in target and non-target lesions or disease stabilization in patients with solid tumor cancers when administered alone and in combination with pembrolizumab or nivolumab." Phase 1 data show early signals of activity with disease stabilization in patients refractory to standard of care and those who have progressed on KEYTRUDA or OPDIVO. agenT-797 preferentially kills tumor-promoting M2 macrophages while preserving pro-inflammatory M1 macrophages associated with anti-tumor responses. agenT-797 can be dosed up to 1000x106 cells without lymphodepletion showing no signs of neurotoxicity and cytokine release syndrome. agenT-797 shows 70% survival in severe viral ARDS compared to site reference controls; potential for a variant agnostic approach to infections. In Phase 1/2 study, agenT-797 shows survival of 70% in mechanically ventilated patients compared to ~10% in a comparative case control population: Increased 90-day survival in a subgroup of patients on respiratory bypass of 75% compared to 30% in a comparative cohort with median survival of 119.5 vs 47 days. agenT-797 demonstrates a favorable safety profile. MiNK's FAP-CAR-iNKT therapeutic candidate, MiNK-215, demonstrates robust efficacy in non small cell lung cancer preclinical models, promoting curative responses, eliminating tumor burden in the lungs, and enhancing tumor specific CD8+ T cell infiltration through tumor stroma. FAP-CAR-iNKT demonstrates a drastic increase of CD8+ T cells infiltrating the tumor and significantly increased tumor killing compared to T cells in murine models. MiNK-413 is a differentiated allogeneic IL-15-armored-BCMA-CAR-iNKT therapeutic candidate, a next generation approach designed to overcome the limitations of current autologous cell therapies. MiNK-413 demonstrates superior tumor clearance in a systemic multiple myeloma models, compared to control BCMA-CAR. MiNK-413 has the potential to target a broader population of patients with multiple myeloma.MiNK's proprietary CARDIS platform enables high-throughput rapid selection and optimization of functional CARs, like MiNK-413 and MiNK-215 .Allo-iNKTs reinvigorate partially exhausted T cells and improve effector functions within the tumor microenvironment; critical mechanisms in rescuing PD-1 refractory tumors. In addition to their direct anti-tumor activity, allogeneic iNKT cellsimprove immune effector function of immune cells in the tumor microenvironment.agenT-797 restores the cytotoxic capacity, activation, and cytokine production of partially exhausted T cells. ShowHide Related Items >><< Street Research Earnings On The Fly INKT MiNK Therapeutics $2.49 / -0.06 (-2.35%) 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright 05/11/22 B. Riley MiNK Therapeutics price target lowered to $7 from $10 at B. Riley 01/24/22 B. Riley MiNK Therapeutics price target lowered to $10 from $24 at B. Riley INKT MiNK Therapeutics $2.49 / -0.06 (-2.35%) 11/03/22 MiNK Therapeutics reports Q3 EPS (19c), consensus (23c) 08/09/22 MiNK Therapeutics reports Q2 EPS (18c), consensus (24c) INKT MiNK Therapeutics $2.49 / -0.06 (-2.35%) 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Conference/Events	Society for Immunotherapy of Cancer to hold a meeting » 04:55 11/10/22 11/10 04:55 11/10/22 04:55 ABMD Abiomed $374.19 / +0.23 (+0.06%) , ADPT Adaptive Biotechnologies $7.25 / -0.53 (-6.82%) , ALKS Alkermes $23.70 / +0.515 (+2.22%) , AMGN Amgen $289.59 / -2.85 (-0.97%) , ASND Ascendis Pharma $122.21 / -1.795 (-1.45%) , BMY Bristol-Myers $79.78 / -0.2398 (-0.30%) , CGEN Compugen / + , CLRB Cellectar Biosciences $1.89 / -0.03 (-1.56%) , CRL Charles River $221.13 / -1.415 (-0.64%) , INKT MiNK Therapeutics $2.49 / -0.06 (-2.35%) , INCY Incyte $77.25 / +0.575 (+0.75%) , PHIO Phio Pharmaceuticals / + , INBX Inhibrx $28.97 / -0.74 (-2.49%) , XNCR Xencor $29.51 / +0.08 (+0.27%) , VCYT Veracyte $23.10 / -1.865 (-7.47%) , TXG 10x Genomics $30.41 / -1.97 (-6.08%) , TPST Tempest Therapeutics $1.44 / -0.18 (-11.11%) , TMO Thermo Fisher $484.63 / -7.6 (-1.54%) , TIL Instil Bio $2.31 / -0.145 (-5.91%) , SGEN Seagen $138.05 / +6.5 (+4.94%) , REGN Regeneron $743.19 / -8.83 (-1.17%) , REPL Replimune Group $17.89 / -0.15 (-0.83%) , RHHBY Roche $41.36 / +0.52 (+1.27%) , DNA Ginkgo Bioworks $2.29 / -0.245 (-9.66%) , CUE Cue Biopharma $2.93 / -0.39 (-11.75%) , IOVA Iovance Biotherapeutics $7.84 / -0.42 (-5.08%) , IPSC Century Therapeutics $10.08 / -0.24 (-2.33%) , LH Labcorp $230.64 / -5.1 (-2.16%) , MRK Merck $101.64 / +0.1 (+0.10%) , MXCT MaxCyte $6.06 / -0.67 (-9.96%) , EXEL Exelixis $16.39 / -0.155 (-0.94%) , FATE Fate Therapeutics $18.78 / -0.79 (-4.04%) , GMAB Genmab $41.30 / +1.38 (+3.46%) 37th Annual Meeting SITC… 37th Annual Meeting SITC 2022 to be held in Boston on November 8-12. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options XNCR VCYT TXG TPST TMO TIL SGEN RHHBY REPL REGN PHIO MXCT MRK LH IPSC IOVA INCY INBX GMAB FATE EXEL DNA CUE CRL CLRB CGEN BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $29.51 / +0.08 (+0.27%) 10/20/22 SpikImm enters non-exclusive in-license agreement with Xencor 08/02/22 Xencor enters multi-year option, license agreement with Caris Life Sciences 05/26/22 Xencor reports initial dose-escalation Phase 1 data of XmAb 104 VCYT Veracyte $23.10 / -1.865 (-7.47%) 10/17/22 Exagen appoints John Aballi as CEO 09/22/22 Veracyte announces VANDAAM trial data published in journal 09/11/22 Veracyte announces new data from Phase 3 of STAMPEDE platform protocol 09/07/22 Veracyte's Envisia Genomic Classifier may predict lung disease progression TXG 10x Genomics $30.41 / -1.97 (-6.08%) 11/03/22 10x Genomics trading resumes 11/03/22 10x Genomics trading halted, volatility trading pause 08/02/22 Singular Genomics appoints Ropp as Chief Commercial Officer 07/14/22 10x Genomics drops 17% to $36.00 after Q2 revenue guidance misses estimates TPST Tempest Therapeutics $1.44 / -0.18 (-11.11%) 10/06/22 Tempest Therapeutics to present on TREX1 at Emerging Technologies summit 08/15/22 Tempest Therapeutics announces near-term milestones 08/15/22 Tempest Therapeutics sees cash runway into 1Q24 06/09/22 Tempest Therapeutics expects cash to fund plans into 1Q24 TMO Thermo Fisher $484.63 / -7.6 (-1.54%) 10/31/22 Cytek Biosciences appoints Chris Williams as COO 10/31/22 Thermo Fisher announces $1B share repurchase program for Q4 10/31/22 Thermo Fisher to acquire The Binding Site Group for $2.6B in accretive deal 10/30/22 Fly Intel: Top five weekend stock stories TIL Instil Bio $2.31 / -0.145 (-5.91%) 11/08/22 Instil Bio announces poster presentations of CoSTAR platform 10/31/22 Instil Bio announces voluntary pause of enrollment in ongoing trials 10/18/22 Instil Bio announces first patient dosed with ITIL-306 09/06/22 Instil Bio appoints Tim Moore as COO SGEN Seagen $138.05 / +6.5 (+4.94%) 09/27/22 Seagen, Zai Lab enter regional collaboration, license agreement for TIVDAK 09/27/22 Seagen to be paid $30M up-front in Zai Lab deal for Tivdak development in China 09/26/22 Seagen, Lava Therapeutics announce exclusive LAVA-1223 license agreement 09/26/22 Seagen, Lava Therapeutics enter worldwide license agreement for LAVA-1223 RHHBY Roche $41.36 / +0.52 (+1.27%) 11/09/22 Roche announces publication of STRONG-HF study 11/07/22 Oncolytics reports interim results from Phase 1/2 GOBLET study 10/27/22 Genentech announces both BALATON, COMINO trials met primary endpoint 10/26/22 Roche announces new ocrelizumab data at ECTRIMS meeting REPL Replimune Group $17.89 / -0.15 (-0.83%) 11/03/22 Replimune Group: Financing extends cash runway into 2025 10/07/22 Replimune Group secures $200M debt financing from Hercules Capital 08/04/22 Replimune Group expects cash to fund operations into 2H of 2024 06/28/22 Revolution Medicines announces election of Patel to board of directors REGN Regeneron $743.19 / -8.83 (-1.17%) 11/09/22 USPTO board says Mylan has shown claims of Regeneron patent 'unpatentable' 11/08/22 Regeneron: FDA approves Libtayo in combination with platinum-based chemotherapy 11/06/22 Intellia presents interim data from cardiomyopathy arm of Phase 1 study of '2001 11/03/22 Regeneron sees FY22 gross margin on net product sales 92.5%-93% PHIO Phio Pharmaceuticals / + 09/22/22 Phio Pharmaceuticals' PH-894 shows increased T-cell persistence 06/06/22 Phio Pharmaceuticals presents outline for first study of PH-762 for melanoma 05/16/22 Phio Pharmaceuticals' PH-894 shows enhanced HER2-CAR-T cell activity MXCT MaxCyte $6.06 / -0.67 (-9.96%) 09/28/22 MaxCyte signs strategic platform license with Vertex Pharmaceuticals 09/21/22 MaxCyte debuts new headquarters in Maryland's I-270 Biotech Corridor 07/12/22 MaxCyte signs strategic platform with LG Chem MRK Merck $101.64 / +0.1 (+0.10%) 11/08/22 Portage Biotech announces clinical trial collaboration agreement with Merck 11/07/22 Merck reports updated systematic literature review of GARDASIL 11/03/22 IO Biotech enters collaboration with Merck for IO101-IO103 11/02/22 Actinium Pharmaceuticals appoints Caroline Yarbrough as Chief Commercial Office LH Labcorp $230.64 / -5.1 (-2.16%) 10/13/22 Labcorp appoints Google Cloud exec Kliphouse to board of directors 08/23/22 Labcorp closes acquisition of RWJBarnabas Health outreach laboratory business 08/15/22 JANA Partners exits Zendesk, boosts stake in New Relic 08/09/22 Becton Dickinson, Labcorp announce CDx collaboration agreement IPSC Century Therapeutics $10.08 / -0.24 (-2.33%) 10/03/22 Century Therapeutics appoints Daphne Quimi, Timothy Walbert to board 08/25/22 Century Therapeutics receives Study May Proceed notification for CNTY-101 08/11/22 Century Therapeutics expects cash to fund operations into 2025 07/01/22 Century Therapeutics Inc trading resumes IOVA Iovance Biotherapeutics $7.84 / -0.42 (-5.08%) 11/07/22 Iovance Biotherapeutics announces updated clinical data for Lifileucel 10/10/22 Iovance Biotherapeutics doses first patient with PD-1 inactivated TIL therapy 08/25/22 Iovance Biotherapeutics initiates BLA submission for lifileucel 06/02/22 Iovance Biotherapeutics director buys $6.6M in common stock INCY Incyte $77.25 / +0.575 (+0.75%) 11/07/22 Incyte, Mirati Therapeutics enter INCB99280 clinical trial and supply pact 10/19/22 Incyte's ruxolitinib cream shows repigmentation efficacy in Phase 3 trial 10/12/22 BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate 10/12/22 BriaCell adds new site to Phase 1/2 trial of advanced breast cancer candidate INBX Inhibrx $28.97 / -0.74 (-2.49%) 10/04/22 Inhibrx announce potential to pursue accelerated approval in U.S. for INBRX-101 08/15/22 Inhibrx: EMA grants orphan drug designation to INBRX-109 06/30/22 Inhibrx completes Phase 1 dose escalation for INBRX-105, draws $60M loan 05/16/22 Inhibrx's INBRX-101 shows favorable safety profile in Phase 1 AATD trial GMAB Genmab $41.30 / +1.38 (+3.46%) 10/28/22 Genmab submits subcutaneous epcoritamab BLA to FDA 10/28/22 AbbVie: EMA validates MAA for epcoritamab 10/18/22 Genmab reports Q3 worldwide net sales of DARZALEX $2.05B FATE Fate Therapeutics $18.78 / -0.79 (-4.04%) 11/07/22 Fate announces exercise by ONO of option to FT825/ONO-8250 08/11/22 Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today 08/09/22 Fate Therapeutics announces preclinical study results on iPSCs 06/30/22 Fate Therapeutics appoints Brian Powl Chief Commercial Officer EXEL Exelixis $16.39 / -0.155 (-0.94%) 11/01/22 Exelixis, Cybrexa establish exclusive collaboration 11/01/22 Exelixis, Sairopa establish development collaboration, option agreement 10/26/22 Exelixis announces initial results from dose-escalation stage of JEWEL-101 10/04/22 Exelixis expands pact with Bristol-Myers for STELLAR-002 trial with combos DNA Ginkgo Bioworks $2.29 / -0.245 (-9.66%) 10/25/22 Ginkgo Bioworks selected by Saudi Arabia for biotechnology initiatives 10/20/22 Ginkgo Bioworks collaborates with Bolt Threads for optimization of Mylo material 10/19/22 Ginkgo Bioworks completes acquisition of Zymergen 10/11/22 Cathie Wood's ARK reports 10.64% stake in Ginkgo Bioworks CUE Cue Biopharma $2.93 / -0.39 (-11.75%) 10/04/22 Cue Biopharma's CUE-101 granted Fast Track designation for treatment of NSCC 09/07/22 Cue Biopharma to present at two September scientific conferences 08/22/22 Cue Biopharma doses 1st patient in CUE-102 study for Wilms' Tumor cancer 05/26/22 Cue Biopharma to present interim data on CUE-101 in head and neck cancer CRL Charles River $221.13 / -1.415 (-0.64%) 11/07/22 Charles River expands CDMO facility in Memphis 11/02/22 Charles River rises 10.6% 11/02/22 Charles River: 'Well-positioned' to finish 2022 on strong note 11/02/22 Charles River to divest Avian Vaccine unit for $170M in cash plus payments CLRB Cellectar Biosciences $1.89 / -0.03 (-1.56%) 10/21/22 Cellectar announces concurrent registered direct, private placement offerings 09/22/22 Cellectar awarded $2M grant to expand Phase 1 study iopofosine I 131 09/13/22 Cellectar announces publication of data from its Phase 2 CLOVER-1 study 08/05/22 Cellectar Biosciences expects cash to fund operations into 3Q23 CGEN Compugen / + 11/07/22 Compugen's COM701 shows preliminary anti-tumor activity in MSS-CRC patients 11/03/22 Compugen announces receipt of Nasdaq delisting notice 09/12/22 Compugen names Alberto Sessa as CFO 08/24/22 Compugen awarded new patent from Japan Patent Office BMY Bristol-Myers $79.78 / -0.2398 (-0.30%) 11/07/22 Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports 11/03/22 Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital 10/31/22 Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints 10/27/22 Obsidian Therapeutics announces extension of agreement with Bristol-Myers ASND Ascendis Pharma $122.21 / -1.795 (-1.45%) 10/31/22 Ascendis announces FDA accepted priority review of its NDA for TransCon PTH 10/03/22 Crinetics appoints Dana Pizzuti as CDO 10/03/22 Ascendis announces recommended Phase 2 dose for transcendIT-101 09/12/22 Ascendis Pharma announces new Week 110 data from Phase 2 PaTH Forward Trial AMGN Amgen $289.59 / -2.85 (-0.97%) 11/09/22 Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead 11/09/22 Arrowhead sells royalty interest in olpasiran to Royalty Pharma for $250M+ 11/07/22 Amgen presents new Repatha data at AHA 2022 11/06/22 Amgen presents end-of-treatment data from Phase 2 OCEAN(a)-DOSE study ALKS Alkermes $23.70 / +0.515 (+2.22%) 11/02/22 Alkermes announces plans to separate oncology business 10/16/22 Acorda announces $16.5M award, royalty/supply relief in AMPYRA arbitration case 10/07/22 Sarissa Capital reports 8.55% stake in Alkermes, may seek to boost stake 07/06/22 Sarissa to vote for Alkermes director slate, still seeks board seat ADPT Adaptive Biotechnologies $7.25 / -0.53 (-6.82%) 10/11/22 Adaptive Biotechnologies partners with Epic to increase access to MRD monitoring 08/25/22 Cathie Wood's ARK Investment bought 155.4K shares of Adaptive Biotech today 07/28/22 Adaptive Biotechnologies receives expanded Medicare coverage of clonoSEQ 06/15/22 Adaptive Biotechnologies launches T-Detect Lyme ABMD Abiomed $374.19 / +0.23 (+0.06%) 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 11/01/22 J&J: Abiomed acquisition has enterprise value of $16.6B 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 10/31/22 Abiomed announces Impella RP Flex with SmartAssist receives FDA PMA ABMD ADPT ALKS AMGN ASND BMY CGEN CLRB CRL INKT INCY PHIO INBX XNCR VCYT TXG TPST TMO TIL SGEN REGN REPL RHHBY DNA CUE IOVA IPSC LH MRK MXCT EXEL FATE GMAB ABMD Abiomed $374.19 / +0.23 (+0.06%) 11/02/22 Morgan Stanley Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/22 Deutsche Bank Abiomed downgraded to Hold from Buy at Deutsche Bank 11/01/22 William Blair Abiomed downgraded to Market Perform from Outperform at William Blair 11/01/22 Piper Sandler Abiomed downgraded to Neutral from Overweight at Piper Sandler ADPT Adaptive Biotechnologies $7.25 / -0.53 (-6.82%) 10/26/22 Piper Sandler Natera named top pick in minimal residual disease at Piper Sandler 10/26/22 Piper Sandler Adaptive price target lowered to $7.50 from $12 at Piper Sandler 08/24/22 Credit Suisse Adaptive Biotechnologies initiated with an Underperform at Credit Suisse 08/17/22 Piper Sandler Adaptive Biotechnologies price target raised to $12 from $7.50 at Piper Sandler ALKS Alkermes $23.70 / +0.515 (+2.22%) 11/03/22 Piper Sandler Alkermes upgraded to Overweight from Neutral at Piper Sandler 10/20/22 Mizuho Alkermes Q3 miss may be largely priced in, says Mizuho 10/19/22 Piper Sandler Alkermes shares have more downside risk, says Piper Sandler 10/14/22 BofA Alkermes upgraded to Neutral at BofA on improved risk/reward AMGN Amgen $289.59 / -2.85 (-0.97%) 11/08/22 Oppenheimer Amgen price target raised to $300 from $290 at Oppenheimer 11/08/22 Truist Amgen price target raised to $280 from $266 at Truist 11/04/22 Piper Sandler Amgen price target raised to $278 from $265 at Piper Sandler 10/31/22 Barclays Amgen downgraded to Underweight from Equal Weight at Barclays ASND Ascendis Pharma $122.21 / -1.795 (-1.45%) 11/03/22 Oppenheimer Ascendis Pharma price target raised to $150 from $144 at Oppenheimer 11/03/22 Wedbush Ascendis Pharma price target raised to $151 from $144 at Wedbush 11/03/22 Credit Suisse Ascendis Pharma price target raised to $130 from $123 at Credit Suisse 11/03/22 Citi Ascendis Pharma price target raised to $163 from $157 at Citi BMY Bristol-Myers $79.78 / -0.2398 (-0.30%) 11/02/22 Evercore ISI Evercore starts Legend Biotech with an Outperform on Carvykti potential 10/31/22 Guggenheim 2seventy Bio initiated with a Buy at Guggenheim 10/12/22 Barclays Bristol-Myers price target lowered to $66 from $69 at Barclays 10/10/22 Guggenheim Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials CGEN Compugen / + 08/23/22 Truist Compugen price target lowered to $4 from $14 at Truist 08/08/22 JMP Securities Compugen price target lowered to $4 from $8 at JMP Securities 08/05/22 Jefferies Jefferies downgrades Compugen to Hold with cash likely becoming 'growing issue' 08/05/22 Jefferies Compugen downgraded to Hold from Buy at Jefferies CLRB Cellectar Biosciences $1.89 / -0.03 (-1.56%) 11/08/22 Maxim Cellectar Biosciences price target lowered to $7 from $12.50 at Maxim 11/04/22 Oppenheimer Cellectar Biosciences price target lowered to $12 from $47 at Oppenheimer 07/18/22 Oppenheimer Cellectar Biosciences assumed with an Outperform at Oppenheimer 04/07/22 Ladenburg Cellectar Biosciences transferred with a Buy at Ladenburg CRL Charles River $221.13 / -1.415 (-0.64%) 11/03/22 Credit Suisse Charles River price target lowered to $280 from $285 at Credit Suisse 09/30/22 Jefferies Charles River upgraded to Buy at Jefferies on nonhuman primate tailwinds 09/29/22 Jefferies Charles River upgraded to Buy from Hold at Jefferies 08/24/22 Credit Suisse Charles River initiated with an Outperform at Credit Suisse INKT MiNK Therapeutics $2.49 / -0.06 (-2.35%) 08/10/22 H.C. Wainwright MiNK Therapeutics initiated with a Buy at H.C. Wainwright 05/11/22 B. Riley MiNK Therapeutics price target lowered to $7 from $10 at B. Riley 01/24/22 B. Riley MiNK Therapeutics price target lowered to $10 from $24 at B. Riley INCY Incyte $77.25 / +0.575 (+0.75%) 10/24/22 JPMorgan Incyte price target lowered to $80 from $86 at JPMorgan 08/03/22 Evercore ISI Incyte downgraded to In Line from Outperform at Evercore ISI 08/03/22 Guggenheim Incyte downgraded to Neutral at Guggenheim after Opzelura Q2 miss 08/03/22 Oppenheimer Incyte price target lowered to $98 from $109 at Oppenheimer PHIO Phio Pharmaceuticals / + INBX Inhibrx $28.97 / -0.74 (-2.49%) 10/05/22 Evercore ISI Inhibrx price target raised to $60 from $54 at Evercore ISI 08/09/22 Credit Suisse Inhibrx price target lowered to $48 from $53 at Credit Suisse 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko 03/15/22 SMBC Nikko Inhibrx initiated with an Outperform at SMBC Nikko XNCR Xencor $29.51 / +0.08 (+0.27%) 11/09/22 Canaccord Xencor price target lowered to $48 from $50 at Canaccord 11/08/22 Raymond James Xencor added to Analyst Current Favorites list at Raymond James 10/13/22 Raymond James Xencor upgraded to Strong Buy from Outperform at Raymond James 10/13/22 Raymond James Xencor upgraded to Strong Buy from Outperform at Raymond James VCYT Veracyte $23.10 / -1.865 (-7.47%) 05/04/22 Needham Veracyte price target lowered to $26 from $31 at Needham 03/15/22 Needham Needham drops Veracyte target, says shares undervalued 03/01/22 Lake Street Veracyte price target lowered to $50 from $95 at Lake Street 03/01/22 Needham Veracyte price target lowered to $35 from $55 at Needham TXG 10x Genomics $30.41 / -1.97 (-6.08%) 11/03/22 JPMorgan 10x Genomics price target lowered to $55 from $65 at JPMorgan 08/18/22 Goldman Sachs 10x Genomics downgraded to Sell from Neutral at Goldman Sachs 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler 08/10/22 Morgan Stanley 10x Genomics price target lowered to $70 from $100 at Morgan Stanley TPST Tempest Therapeutics $1.44 / -0.18 (-11.11%) 09/15/22 Ladenburg Tempest Therapeutics initiated with a Buy at Ladenburg 05/13/22 Piper Sandler Tempest Therapeutics price target lowered to $10 from $20 at Piper Sandler 05/13/22 H.C. Wainwright Tempest Therapeutics price target lowered to $35 from $51 at H.C. Wainwright 04/27/22 Piper Sandler Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20 TMO Thermo Fisher $484.63 / -7.6 (-1.54%) 11/01/22 Baird Thermo Fisher price target lowered to $665 from $695 at Baird 10/27/22 Morgan Stanley Thermo Fisher price target lowered to $613 from $678 at Morgan Stanley 10/27/22 Baird Thermo Fisher price target lowered to $696 from $711 at Baird 10/27/22 Citi Thermo Fisher price target lowered to $650 from $715 at Citi TIL Instil Bio $2.31 / -0.145 (-5.91%) 11/01/22 TD Cowen Cowen downgrades Instil Bio on manufacturing failures 11/01/22 Truist Instil Bio downgraded to Hold from Buy at Truist 11/01/22 Baird Instil Bio price target lowered to $24 from $31 at Baird 11/01/22 TD Cowen Instil Bio downgraded to Market Perform from Outperform at Cowen SGEN Seagen $138.05 / +6.5 (+4.94%) 10/28/22 Oppenheimer Seagen price target lowered to $188 from $208 at Oppenheimer 10/28/22 H.C. Wainwright Seagen price target lowered to $180 from $200 at H.C. Wainwright 10/24/22 JPMorgan Seagen price target lowered to $155 from $194 at JPMorgan 10/11/22 BMO Capital Seagen upgraded to Outperform from Market Perform at BMO Capital REGN Regeneron $743.19 / -8.83 (-1.17%) 11/09/22 RBC Capital Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital 11/09/22 Truist Regeneron price target raised to $856 from $790 at Truist 11/03/22 Piper Sandler Regeneron price target lowered to $765 from $775 at Piper Sandler 10/31/22 EF Hutton Regeneron initiated with a Buy at EF Hutton REPL Replimune Group $17.89 / -0.15 (-0.83%) 10/14/22 BMO Capital Replimune Group price target raised to $40 from $30 at BMO Capital 08/16/22 Piper Sandler Replimune Group price target lowered to $43 from $44 at Piper Sandler 05/24/22 Wedbush Replimune Group price target lowered to $52 from $59 at Wedbush 05/19/22 Piper Sandler Replimune Group price target lowered to $44 from $52 at Piper Sandler RHHBY Roche $41.36 / +0.52 (+1.27%) 10/25/22 Capital One Arvinas initiated with an Overweight at Capital One 10/17/22 Morgan Stanley Roche's AD drug expected to fall short in trial, says Morgan Stanley 10/12/22 Stifel Biogen upgraded to Buy from Hold at Stifel 10/11/22 Morgan Stanley Arcus Biosciences initiated with an Overweight at Morgan Stanley DNA Ginkgo Bioworks $2.29 / -0.245 (-9.66%) 10/04/22 Morgan Stanley Ginkgo Bioworks initiated with an Equal Weight at Morgan Stanley 08/16/22 BTIG Ginkgo Bioworks price target raised to $6 from $5 at BTIG 08/16/22 Raymond James Ginkgo Bioworks price target raised to $14.50 from $11.50 at Raymond James 07/26/22 William Blair Zymergen buyout deal 'best case scenario,' says William Blair CUE Cue Biopharma $2.93 / -0.39 (-11.75%) 08/24/22 Oppenheimer Cue Biopharma price target lowered to $10 from $26 at Oppenheimer 03/23/22 JMP Securities Cue Biopharma price target lowered to $15 from $30 at JMP Securities 03/21/22 Oppenheimer Cue Biopharma price target lowered to $26 from $32 at Oppenheimer 03/18/22 Craig-Hallum Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum IOVA Iovance Biotherapeutics $7.84 / -0.42 (-5.08%) 10/31/22 Guggenheim Iovance Biotherapeutics initiated with a Neutral at Guggenheim 08/18/22 Wells Fargo Iovance Biotherapeutics assumed with an Equal Weight at Wells Fargo 08/08/22 Stifel Global Blood Therapeutics downgraded to Hold from Buy at Stifel IPSC Century Therapeutics $10.08 / -0.24 (-2.33%) 10/31/22 Guggenheim Century Therapeutics initiated with a Buy at Guggenheim 10/10/22 Canaccord Century Therapeutics initiated with a Buy at Canaccord 06/10/22 Roth MKM Century Therapeutics initiated with a Buy at Roth Capital 05/23/22 H.C. Wainwright Century Therapeutics initiated with a Buy at H.C. Wainwright LH Labcorp $230.64 / -5.1 (-2.16%) 11/03/22 Mizuho Labcorp price target lowered to $250 from $296 at Mizuho 10/28/22 Citi Labcorp price target lowered to $275 from $300 at Citi 10/28/22 Baird Labcorp price target lowered to $270 from $297 at Baird 09/19/22 Argus Labcorp downgraded to Hold from Buy at Argus MRK Merck $101.64 / +0.1 (+0.10%) 11/01/22 Oppenheimer Merck pact shows Veeva life science vendor of choice, says Oppenheimer 11/01/22 Guggenheim Merck price target raised to $111 from $104 at Guggenheim 10/28/22 Morgan Stanley Merck price target raised to $100 from $91 at Morgan Stanley 10/28/22 Cantor Fitzgerald Merck price target raised to $120 from $107 at Cantor Fitzgerald MXCT MaxCyte $6.06 / -0.67 (-9.96%) 08/14/22 BTIG MaxCyte price target raised to $11 from $10 at BTIG EXEL Exelixis $16.39 / -0.155 (-0.94%) 11/02/22 TD Cowen Exelixis price target lowered to $21 from $26 at Cowen 10/31/22 EF Hutton Exelixis initiated with a Buy at EF Hutton 10/18/22 JMP Securities Exelixis initiated with an Outperform at JMP Securities 10/12/22 Guggenheim Initial data for Exelixis's XB002 show encouraging safety, says Guggenheim FATE Fate Therapeutics $18.78 / -0.79 (-4.04%) 11/04/22 Cantor Fitzgerald Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald 10/10/22 Canaccord Fate Therapeutics initiated with a Buy at Canaccord 08/18/22 Wells Fargo Fate Therapeutics assumed with an Overweight at Wells Fargo 08/04/22 Oppenheimer Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer GMAB Genmab $41.30 / +1.38 (+3.46%) 10/17/22 DNB Markets Genmab downgraded to Hold from Buy at DNB Markets 09/15/22 Credit Suisse Genmab price target raised to DKK 2,800 from DKK 2,600 at Credit Suisse 08/22/22 H.C. Wainwright Genmab price target raised to $51 from $49 at H.C. Wainwright 08/12/22 JPMorgan Genmab price target raised to DKK 2,900 from DKK 2,700 at JPMorgan XNCR VCYT TXG TPST TMO TIL SGEN RHHBY REPL REGN MXCT MRK LH IPSC IOVA INKT INCY INBX GMAB FATE EXEL DNA CUE CRL CLRB BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $29.51 / +0.08 (+0.27%) 11/07/22 Xencor reports Q3 EPS (55c), consensus (68c) 08/03/22 Xencor reports Q2 EPS (57c), consensus (44c) VCYT Veracyte $23.10 / -1.865 (-7.47%) 11/02/22 Veracyte raises FY2 revenue view to $288M-$293M from $272M-$280M 11/02/22 Veracyte reports Q3 EPS (12c), consensus (25c) 08/02/22 Veracyte raises FY22 revenue view to $272M-$280M, consensus $272.42M 08/02/22 Veracyte reports Q2 EPS (13c), consensus (22c) TXG 10x Genomics $30.41 / -1.97 (-6.08%) 11/02/22 10x Genomics sees 2022 revenue $500M-$522M, consensus $509.87M 11/02/22 10x Genomics reports Q3 EPS (37c), consensus (46c) 08/08/22 10x Genomics updated FY22 revenue view to $500M-$520M, consensus $571.06M 08/08/22 10x Genomics reports Q2 EPS (57c), consensus (39c) TPST Tempest Therapeutics $1.44 / -0.18 (-11.11%) 11/08/22 Tempest Therapeutics reports Q3 EPS (66c), consensus (80c) 08/15/22 Tempest Therapeutics reports Q2 EPs (79c) vs. ($7.63) last year. 05/13/22 Tempest Therapeutics reports Q1 EPS ($1.18), consensus ($1.12) TMO Thermo Fisher $484.63 / -7.6 (-1.54%) 10/26/22 Thermo Fisher raises FY22 EPS view to $23.01 from $22.93, consensus $22.95 10/26/22 Thermo Fisher reports Q3 adjusted EPS $5.08, consensus $4.82 TIL Instil Bio $2.31 / -0.145 (-5.91%) 08/12/22 Instil Bio reports Q2 adjusted EPS (40c), consensus (41c) 05/16/22 Instil Bio reports Q1 EPS (42c), consensus (38c) SGEN Seagen $138.05 / +6.5 (+4.94%) 10/27/22 Seagen raises FY22 revenue $1.82B-$1.865B from $1.71B-$1.795B 10/27/22 Seagen reports Q3 EPS ($1.03), consensus (95c) 07/28/22 Seagen raises FY22 revenue view to $1.71B-$1.795B from $1.665B-$1.745B 07/28/22 Seagen reports Q2 EPS (73c), consensus (86c) RHHBY Roche $41.36 / +0.52 (+1.27%) 10/18/22 Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year 07/21/22 Roche reports 1H core EPS CHF 11.76 vs. CHF 10.56 last year REPL Replimune Group $17.89 / -0.15 (-0.83%) 11/03/22 Replimune Group reports Q2 EPS (79c), consensus (78c) 08/04/22 Replimune Group reports Q1 EPS (78c) vs (53c) last year 05/19/22 Replimune Group reports 2022 EPS ($2.26), consensus ($2.26) REGN Regeneron $743.19 / -8.83 (-1.17%) 11/03/22 Regeneron reports Q3 EPS $11.14, consensus $9.48 11/02/22 Notable companies reporting before tomorrow's open 08/03/22 Regeneron reports Q2 EPS $9.77, consensus $9.54 MXCT MaxCyte $6.06 / -0.67 (-9.96%) 11/09/22 MaxCyte reports Q3 EPS (6c) consensus (9c) 08/10/22 MaxCyte sees FY22 core business revenue growth of 30% year-over-year 08/10/22 MaxCyte reports Q2 EPS (8c), consensus (8c) MRK Merck $101.64 / +0.1 (+0.10%) 10/27/22 Merck raises FY22 adjusted EPS view to $7.32-$7.37 from $7.25-$7.35 10/27/22 Merck reports Q3 adjusted EPS $1.85, consensus $1.71 10/26/22 Notable companies reporting before tomorrow's open LH Labcorp $230.64 / -5.1 (-2.16%) 10/27/22 Labcorp sees FY22 EPS $19.25- $20.25 , consensus $20.19 10/27/22 Labcorp reports Q3 EPS $4.68, consensus $4.67 07/28/22 LabCorp raises FY22 adjusted EPS view to $19.00-$21.25 from $18.25-$21.00 07/28/22 LabCorp reports Q2 adjusted EPS $4.96, consensus $4.70 IPSC Century Therapeutics $10.08 / -0.24 (-2.33%) 08/11/22 Century Therapeutics reports Q2 EPS (54c), consensus (52c) 05/16/22 Century Therapeutics reports Q1 EPS (66c), consensus (45c) IOVA Iovance Biotherapeutics $7.84 / -0.42 (-5.08%) 11/03/22 Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c) 08/04/22 Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c) INKT MiNK Therapeutics $2.49 / -0.06 (-2.35%) 11/03/22 MiNK Therapeutics reports Q3 EPS (19c), consensus (23c) 08/09/22 MiNK Therapeutics reports Q2 EPS (18c), consensus (24c) 05/10/22 MiNK Therapeutics reports Q1 EPS (23c), consensus (21c) INCY Incyte $77.25 / +0.575 (+0.75%) 11/01/22 Incyte reports Q3 EPS 60c, consensus 72c 08/02/22 Incyte reports Q2 EPS $1.01, consensus 76c INBX Inhibrx $28.97 / -0.74 (-2.49%) 11/07/22 Inhibrx reports Q3 EPS (90c), consensus (94c) 08/08/22 Inhibrx reports Q2 EPS (97c), consensus (78c) GMAB Genmab $41.30 / +1.38 (+3.46%) 08/10/22 Genmab reports operating profit of DKK 1.761B for first half, up from DKK 1.32B 08/08/22 Genmab raises 2022 sales outlook to DKK 12B-13B from DKK 11B-12B 05/11/22 Genmab narrows 2022 revenue view DKK 11B - DKK 12B from DKK 10.8B - DKK 12B 05/11/22 Genmab reports Q1 revenue DKK 2.1B vs. DKK 1.58B last year FATE Fate Therapeutics $18.78 / -0.79 (-4.04%) 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) EXEL Exelixis $16.39 / -0.155 (-0.94%) 11/01/22 Exelixis sees FY22 revenue $1.575B-$1.6B, consensus $1.6B 11/01/22 Exelixis reports Q3 adjusted EPS 31c, consensus 19c 08/09/22 Exelixis reports Q2 EPS 28c, consensus 19c 05/10/22 Exelixis sees FY22 revenue $1.525B-$1.625B, consensus $1.64B DNA Ginkgo Bioworks $2.29 / -0.245 (-9.66%) 08/15/22 Ginkgo Bioworks raises FY22 revenue view to $425M-$440M from $375M-$390M 08/15/22 Ginkgo Bioworks reports Q2 EPS (41c), consensus (4c) 05/16/22 Ginkgo Bioworks sees FY22 revenue view to $375M-$390M from $325M-$340M 05/16/22 Ginkgo Bioworks reports Q1 revenue $168M, consensus $105.68M CUE Cue Biopharma $2.93 / -0.39 (-11.75%) 05/10/22 Cue Biopharma reports Q1 EPS (44c), consensus (43c) CRL Charles River $221.13 / -1.415 (-0.64%) 11/02/22 Charles River sees Q4 adjusted EPS $2.65-$2.80, consensus $2.73 11/02/22 Charles River narrows FY22 adjusted EPS view to $10.80-$10.95, consensus $10.80 11/02/22 Charles River reports Q3 adjusted EPS $2.63, consensus $2.49 08/03/22 Charles River sees Q3 adjusted EPS down in high single digits vs. 3Q21 CLRB Cellectar Biosciences $1.89 / -0.03 (-1.56%) 11/03/22 Cellectar Biosciences reports Q3 EPS ($1.28), consensus ($1.21) 08/05/22 Cellectar Biosciences reports Q2 EPS ($1.22), consensus ($1.03) 05/10/22 Cellectar Biosciences reports Q1 EPS (10c), consensus (10c) BMY Bristol-Myers $79.78 / -0.2398 (-0.30%) 10/25/22 Notable companies reporting before tomorrow's open 10/25/22 Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51 10/25/22 Bristol-Myers reports Q3 EPS $1.99, consensus $1.83 ASND Ascendis Pharma $122.21 / -1.795 (-1.45%) 11/02/22 Ascendis Pharma reports Q3 EPS ( EUR 3.03) vs. (EUR 1.47) last year 08/10/22 Ascendis Pharma reports Q2 EPS EUR (1.46) vs EUR (2.50) last year 05/11/22 Ascendis Pharma reports Q1 EPS EUR (2.21) vs. EUR (1.17) AMGN Amgen $289.59 / -2.85 (-0.97%) 11/03/22 Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00 11/03/22 Amgen reports Q3 adjusted EPS $4.70, consensus $4.44 11/03/22 Notable companies reporting after market close 08/04/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.40 ALKS Alkermes $23.70 / +0.515 (+2.22%) 11/02/22 Alkermes raises FY22 adjusted EPS view to 15c-33c from 9c-27c, consensus 20c 11/02/22 Alkermes reports Q3 adjusted EPS 2c, consensus 3c 07/27/22 Alkermes raises FY22 adjusted EPS view to 9c-27c from (18c)-0c, consensus 4c 07/27/22 Alkermes reports Q2 adjusted EPS 6c, consensus 1c ADPT Adaptive Biotechnologies $7.25 / -0.53 (-6.82%) 11/03/22 Adaptive Biotechnologies narrows FY22 revenue view to $185M-$190M 11/03/22 Adaptive Biotechnologies reports Q3 EPS (32c), consensus (38c) 08/03/22 Adaptive Biotechnologiesbacks FY22 revenue $185M-$195M, consensus $187.62M 08/03/22 Adaptive Biotechnologies reports Q2 EPS (37c), consensus (43c) ABMD Abiomed $374.19 / +0.23 (+0.06%) 11/01/22 Abiomed reports Q2 EPS $1.30, consensus $1.04 TMO SGEN REGN MRK LH BMY AMGN TMO Thermo Fisher $484.63 / -7.6 (-1.54%) 10/30/22 Thermo Fisher said to near $2.3B deal for Binding Site, Bloomberg reports SGEN Seagen $138.05 / +6.5 (+4.94%) 08/26/22 Merck's Seagen bid hit snag over price concerns, Bloomberg reports 08/25/22 Merck's bid for Seagen stalled on price concerns, Bloomberg reports 07/15/22 Merck deal for Seagen unlikely to be completed by earnings, WSJ reports 07/07/22 Merck offers around $200 per share for Seagen, FT reports REGN Regeneron $743.19 / -8.83 (-1.17%) 09/16/22 WHO panel recommends against GSK, Regeneron COVID drugs, Bloomberg reports MRK Merck $101.64 / +0.1 (+0.10%) 10/07/22 Merck's Lagevrio sped COVID recovery, didn't lower hospital risk, STAT says LH Labcorp $230.64 / -5.1 (-2.16%) 07/28/22 LabCorp planning clinical development business unit spinoff, WSJ reports BMY Bristol-Myers $79.78 / -0.2398 (-0.30%) 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 06/24/22 Judge says Bristol-Myers must face $6.4B Breyanzi lawsuit, Reuters says 06/14/22 FTC asked to investigate price hikes by Janssen, Bristol-Myers, STAT says 05/28/22 Buy Bristol-Myers, rally just getting started, Barron's says AMGN Amgen $289.59 / -2.85 (-0.97%) 11/04/22 Supreme Court to hear Amgen appeal in Repatha patent dispute, Bloomberg says 08/01/22 Amgen battles IRS over $10.7B in back taxes, WSJ reports XNCR VCYT TXG TMO TIL SGEN RHHBY REGN MRK LH IOVA INKT INCY INBX FATE EXEL DNA CUE CRL CGEN BMY ASND AMGN ALKS ADPT ABMD XNCR Xencor $29.51 / +0.08 (+0.27%) 09/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations VCYT Veracyte $23.10 / -1.865 (-7.47%) 11/07/22 Biotech Alert: Searches spiking for these stocks today 07/13/22 Fly Intel: After-Hours Movers TXG 10x Genomics $30.41 / -1.97 (-6.08%) 07/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/15/22 What You Missed On Wall Street On Friday 07/15/22 What You Missed On Wall Street This Morning 07/14/22 Fly Intel: After-Hours Movers TMO Thermo Fisher $484.63 / -7.6 (-1.54%) 10/31/22 What You Missed On Wall Street On Monday 10/31/22 What You Missed On Wall Street This Morning 10/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations TIL Instil Bio $2.31 / -0.145 (-5.91%) 10/31/22 Fly Intel: Pre-market Movers SGEN Seagen $138.05 / +6.5 (+4.94%) 10/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/26/22 What You Missed On Wall Street On Friday 08/26/22 What You Missed On Wall Street This Morning 07/18/22 What You Missed On Wall Street On Monday RHHBY Roche $41.36 / +0.52 (+1.27%) 10/24/22 Biotech Alert: Searches spiking for these stocks today 10/13/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/02/22 What You Missed On Wall Street This Morning REGN Regeneron $743.19 / -8.83 (-1.17%) 10/29/22 Buy/Sell: Wall Street's top 10 stock calls this week 10/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations MRK Merck $101.64 / +0.1 (+0.10%) 10/27/22 What You Missed On Wall Street On Thursday 10/27/22 What You Missed On Wall Street This Morning 10/27/22 Fly Intel: Pre-market Movers LH Labcorp $230.64 / -5.1 (-2.16%) 09/19/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/22/22 What You Missed On Wall Street On Monday 08/22/22 What You Missed On Wall Street This Morning 08/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations IOVA Iovance Biotherapeutics $7.84 / -0.42 (-5.08%) 05/27/22 What You Missed On Wall Street On Friday 05/27/22 What You Missed On Wall Street This Morning 05/26/22 Fly Intel: After-Hours Movers INKT MiNK Therapeutics $2.49 / -0.06 (-2.35%) 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations INCY Incyte $77.25 / +0.575 (+0.75%) 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/28/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations INBX Inhibrx $28.97 / -0.74 (-2.49%) 10/30/22 Sell these stocks now, proven algorithm says 10/04/22 What You Missed On Wall Street On Tuesday 10/04/22 What You Missed On Wall Street This Morning FATE Fate Therapeutics $18.78 / -0.79 (-4.04%) 11/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations EXEL Exelixis $16.39 / -0.155 (-0.94%) 10/04/22 Fly Intel: Pre-market Movers DNA Ginkgo Bioworks $2.29 / -0.245 (-9.66%) 10/05/22 Fly Intel: Pre-market Movers 08/16/22 What You Missed On Wall Street On Tuesday 08/16/22 What You Missed On Wall Street This Morning 08/16/22 Fly Intel: Pre-market Movers CUE Cue Biopharma $2.93 / -0.39 (-11.75%) 10/06/22 Biotech Alert: Searches spiking for these stocks today CRL Charles River $221.13 / -1.415 (-0.64%) 09/30/22 What You Missed On Wall Street On Friday 09/30/22 What You Missed On Wall Street This Morning 09/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CGEN Compugen / + 11/03/22 Biotech Alert: Searches spiking for these stocks today BMY Bristol-Myers $79.78 / -0.2398 (-0.30%) 10/26/22 What You Missed On Wall Street On Wednesday 10/26/22 What You Missed On Wall Street This Morning 10/26/22 Fly Intel: Pre-market Movers 10/20/22 Meet PDS Biotechnology: Fly exclusive interview with CEO Frank Bedu-Addo ASND Ascendis Pharma $122.21 / -1.795 (-1.45%) 10/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations AMGN Amgen $289.59 / -2.85 (-0.97%) 11/08/22 What You Missed On Wall Street On Tuesday 11/08/22 What You Missed On Wall Street This Morning 10/11/22 What You Missed On Wall Street On Tuesday 10/11/22 What You Missed On Wall Street This Morning ALKS Alkermes $23.70 / +0.515 (+2.22%) 11/03/22 What You Missed On Wall Street On Thursday 11/03/22 What You Missed On Wall Street This Morning 11/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ADPT Adaptive Biotechnologies $7.25 / -0.53 (-6.82%) 08/03/22 Fly Intel: After-Hours Movers ABMD Abiomed $374.19 / +0.23 (+0.06%) 11/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/01/22 What You Missed On Wall Street This Morning 11/01/22 Fly Intel: Pre-market Movers 11/11/22 6th Annual IO Next Virtual Summit 11/12/22 ACR Convergence 2022 11/14/22 Data Science Virtual Conference 11/15/22 STAT Summit 2022 12/12/22 ASH Annual Meeting & Expo 2022 11/14/22 Compugen - CGEN 11/14/22 Cue Biopharma - CUE 11/14/22 Ginkgo Bioworks - DNA 11/21/22 Adaptive Biotechnologies - ADPT 02/02/23 Merck - MRK 02/02/23 Bristol-Myers - BMY 01/19/23 Tukysa (Tucatinib in combination with Trastuzumab) 01/29/23 PDUFA Date for new sBLA for KEYTRUDA 02/11/23 PDUFA Date for EYLEA (Aflibercept) Injection 02/28/23 PDUFA 06/16/23 PDUFA Date for CAMZYOS 11/18/22 Genmab 11/21/22 Adaptive Biotechnologies 11/22/22 Compugen 11/28/22 Compugen TMO SGEN REGN MRK IPSC IOVA DNA CRL BMY AMGN ABMD TMO Thermo Fisher $484.63 / -7.6 (-1.54%) 07/21/22 Early notable gainers among liquid option names on July 21st 07/20/22 Thermo Fisher call buyer realizes 52% same-day gains SGEN Seagen $138.05 / +6.5 (+4.94%) 07/28/22 Seattle Genetics options imply 5.8% move in share price post-earnings 07/07/22 Unusually active option classes on open July 7th REGN Regeneron $743.19 / -8.83 (-1.17%) 09/16/22 Early notable gainers among liquid option names on September 16th 09/09/22 Early notable gainers among liquid option names on September 9th 09/08/22 Early notable gainers among liquid option names on September 8th 08/03/22 Early notable gainers among liquid option names on August 3rd MRK Merck $101.64 / +0.1 (+0.10%) 10/10/22 Early notable gainers among liquid option names on October 10th 10/10/22 Unusually active option classes on open October 10th 09/22/22 Unusually active option classes on open September 22nd IPSC Century Therapeutics $10.08 / -0.24 (-2.33%) 06/15/22 Nineteen new option listings on June 15th IOVA Iovance Biotherapeutics $7.84 / -0.42 (-5.08%) 06/27/22 Iovance Biotherapeutics call volume above normal and directionally bullish 06/03/22 Iovance Biotherapeutics call volume above normal and directionally bullish DNA Ginkgo Bioworks $2.29 / -0.245 (-9.66%) 09/22/22 Largest borrow rate increases among liquid names 09/20/22 Largest borrow rate increases among liquid names 09/12/22 Largest borrow rate increases among liquid names 09/08/22 Largest borrow rate increases among liquid names CRL Charles River $221.13 / -1.415 (-0.64%) 11/02/22 Early notable gainers among liquid option names on November 2nd 10/25/22 Early notable gainers among liquid option names on October 25th 09/30/22 Early notable gainers among liquid option names on September 30th BMY Bristol-Myers $79.78 / -0.2398 (-0.30%) 09/29/22 Early notable gainers among liquid option names on September 29th 09/12/22 Early notable gainers among liquid option names on September 12th 09/12/22 Unusually active option classes on open September 12th 09/08/22 Notable open interest changes for September 8th AMGN Amgen $289.59 / -2.85 (-0.97%) 10/11/22 Early notable gainers among liquid option names on October 11th 07/12/22 Amgen put volume heavy and directionally bearish 06/27/22 Amgen put volume heavy and directionally bearish ABMD Abiomed $374.19 / +0.23 (+0.06%) 11/01/22 Early notable gainers among liquid option names on November 1st

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial